ANCILLARY EDUCATIONAL EVENT

Conquer the Clot: Addressing VTE in Your Patients with Cancer
Friday, June 4, 2021, 9:30 AM - 10:45 AM EDT
Faculty: Alok Khorana, MD (Cleveland Clinic Lerner College of Medicine), Michael Streiff, MD (Johns Hopkins University School of Medicine), Tzu-Fei Wang, MD, MPH (The University of Ottawa)

ORAL ABSTRACT SESSIONS

Central Nervous System Tumors – Primary CNS Tumors – Glioma
Authors: Stuart A. Grossman, Louis B. Nabors, Joy D. Fisher, Patrick Y. Wen, William C. Timmer, Frederick G. Barker, David M. Peereboom, Benjamin M. Ellingson, Jeffrey G. Supko, Michelle A. Rudek, Ingo K. Mellinghoff, Tom Mikkelsen, Timothy Francis Cloughesy, Michael Prados, Glenn Jay Lesser, E. Antonio Chiocca, Tracy Batchelor, Susan Marina Chang, Frank S. Lieberman, Xiaobu Ye; Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD; University of Alabama at Birmingham, Birmingham, AL; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Dana-Farber/Brigham and Women's Cancer Center, Boston, MA; Natl Cancer Inst, Bethesda, MD; Massachusetts General Hospital, Boston, MA; Cleveland Clinic, Cleveland, OH; University of California, Los Angeles, CA; SKCCC at Johns Hopkins, Baltimore, MD; Dana-Farber/Brigham and Women's Cancer Center, Boston, MA; University of Pittsburgh Medical Center, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

(2006) Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated gliob
Central Nervous System Tumors – Primary CNS Tumors – Glioma
Authors: Rifaiquat Rahman, Lorenzo Trippa, Geoffrey Fell, Eudocia Quant Lee, Isabel Arrillaga-Romany, Mehdi Touat, Jan Drappatz, Evanthis GaLantis, Manmeet Singh Ahluwalia, Howard Colman, Louis B. Nabors, Jaroslaw T. Hepel, David Schiff, Mary Roberta Welch, David M. Meredith, E. Antonio Chiocca, David A. Reardon, Keith L. Ligon, Brian Michael Alexander, Patrick Y. Wen; Dana-Farber/Brigham and Women's Cancer Center, Boston, MA; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Massachusett General Hospital, Boston, MA; Hôpital Pitié Salpêtrière, Villejuif,
France; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mayo Clinic, Rochester, MN; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; University of Alabama at Birmingham, Birmingham, AL; New England Medc'l Ctr-Tufts Univ, East Greenwich, RI; University of Virginia, Charlottesvville, VA; Montefiore Medical Center, New York, NY; Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA

(2504) COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).
Developmental Therapeutics – Immunotherapy – Antibodies
Daniel A. Vaena, Gini F. Fleming, Bartosz Chmielowski, Manish Sharma, Erika P. Hamilton, Ryan J. Sullivan, Dale Randall Shepard, Kyriakos P. Papadopoulos, Amita Patnaik, Adam ElNaggar, Adeboye H. Adewoye, Robina Smith, Russell A. Lim, Ecaterrina Elena Dumbrava, Drew W. Rasco; West Cancer Center and Research Institute, Memphis, TN; University of Chicago Medicine, Chicago, IL; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; START-Midwest, Grand Rapids, MI; Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Massachusetts General Hospital, Boston, MA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; START-San Antonio, San Antonio, TX; START, San Antonio, TX; West Cancer Center, Memphis, TN; Compugen USA Inc., South San Francisco, CA; Columbia University-Herbert Irving Comprehensive Cancer Center, New York, NY; The University of Texas MD Anderson Cancer Center, Houston, TX

(3002) Phase 2 study of DRD2 antagonist/ClpP agonist ONC201 in neuroendocrine tumors.
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology—Small Molecules
Authors: Peter Meade Anderson, Janette Gortz; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic, Cleveland, OH

(5001) SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).
Genitourinary Cancer—Prostate, Testicular, and Penile - Prostate Cancer - Advanced/Hormone-Sensitive
Authors: Neeraj Agrawal, William K. Kwon, Maha H. A. Hussain, Shilpa Gupta, Melissa Plets, Primo "Lucky" N. Lara, Andrea Harzstark, Przemyslaw Twardowski, Channing Judith Paller, Dylan M. Zylla, Matthew R. Zibelman, Ellis Glenn Levine, Bruce J. Roth, Amir Goldkorn, Daniel A. Vaena, Manish Kohli, Tony Crispino, Nicholas J. Vogelzang, Ian Murchie Thompson, David I. Quinn; University of Utah, Salt Lake City, UT; SWOG Statistics and Data Management Center, Seattle, WA; Northwestern University, Chicago, IL; Cleveland Clinic, Cleveland, OH; University of California, Sacramento, CA; Kaiser Permanente - Oakland, Oakland, CA; John Wayne Cancer Institute, Santa Monica, CA; Johns Hopkins University School of Medicine, Baltimore, MD; Metro Minnesota CCRC/Park Nicollet Clinic, St. Louis Park, MN; Fox Chase Cancer Center, Philadelphia, PA; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Washington University School of Medicine, St. Louis, MO; USC Norris Comprehensive Cancer Center, Los Angeles, CA; University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA; Mayo Clinic, Rochester, MN; UsTOO Prostate Cancer Support and Education Las Vegas Chapter, Las Vegas, NV; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; CHRISTUS Santa Rosa Health System, San Antonio, TX; USC Norris Comprehensive Cancer Center, Los Angeles, CA

(6008) Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).
Head and Neck Cancer – Local-Regional
Authors: Ravindra Upaluri, Rebecca Chernock, Mena Mansour, Ryan Jackson, Jason Rich, Patrik Pipkorn, Randal C Paniello, Sidharth Puram, Jose P. Zevallos, Donald J. Annino, Laura A. Goguen, Luc
(7503) ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia – Non-Hodgkin Lymphoma

Authors: Mitchell Reed Smith, Opeyemi Jegede, Peter Martin, Brian G. Till, Samir S. Parekh, David T Yang, Lale Kostakoglu, Carla Casulo, Nancy L. Bartlett, Paolo Fabrizio Caimi, Tareq Al Baghdadi, Kami J. Maddocks, Mark D. Romer, David James Inwards, Rachel E. Lerner, Lynne I. Wagner, Richard F. Little, Jonathan W. Friedberg, John Paul Leonard, Brad S. Kahl; GW University, Washington, DC; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY; Fred Hutchinson Cancer Resrch Ctr, Seattle, WA; Mount Sinai, New York, NY; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Virginia, Charlottesville, TN; University of Rochester Medical Center-James P. Wilmot Cancer Center, Rochester, NY; Washington University School of Medicine in St. Louis and Siteman Cancer Center, St. Louis, MO; Adult Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH; IHA Hematology Oncology Consultants, Ypsilanti, MI; Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH; Good Samaritan Hospital-Dayton, Kettering, OH; Division of Hematology, Mayo Clinic, Rochester, MN;Fraunshuh Cancer Center and Park Nicollet Institute, Minneapolis, MN; Wake Forest University Health Sciences, Winston-Salem, NC; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; University of Rochester Medical Center, Rochester, NY; Meyer Cancer Center, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY; Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO

(9005) Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC).

Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

Authors: Debora S. Bruno, Lisa M. Hess, Xiaohong Li, Eric Wen Su, Yajun Emily Zhu, Monaliben Patel; The MetroHealth System, Cleveland, OH; Eli Lilly and Company, Indianapolis, IN; University Hospitals Cleveland Medical Center, Cleveland, OH

(9501) Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

Melanoma/Skin Cancers – Local-Regional

Authors: Kenneth F. Grossmann, Megan Othus, Sapna Pradyuman Patel, Ahmad A. Tarhini, Vernon K. Sondak, Teresa M. Petrella, Thach-Giao Truong, Nikhil I. Khushalani, Justine Vanessa Cohen, Elizabeth Iannotti Buchbinder, Kari Lynn Kendra, Pauline Funchain, Karl D. Lewis, Bartosz Chmieleowski, Hongli Li, James Moon, Krishna Soujanya Gunturu, Zeynep Ergulu, John M. Kirkwood, Antoni Ribas; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; SWOG Statistical Center, Seattle, WA; The University of Texas MD Anderson Cancer Center, Houston, TX; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Moffitt Cancer Center, Tampa, FL; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Kaiser Permanente, Dept of Medical Oncology, Vallejo, CA; Department of Cutaneous Oncology, H. Lee...
Cancer Center members indicated in **BOLD**

Moffitt Cancer Center, Tampa, FL; Massachusetts General Hospital, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; The Ohio State University Comprehensive Cancer Center, Department of Internal Medicine, Columbus, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; University of Colorado Comprehensive Cancer Center, Aurora, CO; Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA; SWOG, Seattle, WA; Southwest Oncology Group Statistical Center, Seattle, WA; Lahey Hospital and Medical Center, Burlington, MA; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; University of Pittsburgh Medical Center, Pittsburgh, PA; University of California Los Angeles, Los Angeles, CA

(10502) **Ancestrally unbiased polygenic breast cancer (BC) risk assessment.**
Prevention, Risk Reduction, and Hereditary Cancer – Cancer Prevention
Authors: Elisha Hughes, Placeide Tiemeny, Shannon Gallagher, Stephanie Meek, Charis Eng, Monique Gary, Ora Gordon, Jennifer R. Klemp, Olufunmilayo I. Olopade, Holly Jane Pederson, Jeffrey N. Weitzel, Pat W. Whitworth, Lamis Yehia, Susanne Wagner, Thomas Paul Slavin, Alexander Gutin, Jerry Lanchbury; Myriad Genetics, Inc., Salt Lake City, UT; Genomic Medicine Institute, Cleveland Clinic Lerner Research Institute, Cleveland, OH; Grand View Health, Sellersville, PA; Providence Health & Services, Renton, WA; University of Kansas Cancer Center, Westwood, KS; Center for Clinical Cancer Genetics and Global Health, University of Chicago, Chicago, IL; Medical Breast Services, Cleveland Clinic, Cleveland, OH; Latin American School of Oncology, Sierra Madre, CA; Nashville Breast Center, Nashville, TN

(10503) **Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer.**
Prevention, Risk Reduction, and Hereditary Cancer – Cancer Genetics
Authors: Nima Sharifi, Megan Lynn Kruse, Jeffrey McManus, Yoon-Mi Chung, Wei Wei, Peter Bazeley, Fumihiko Nakamura, Aimalie Hardaway, Erinn Downs Kelley, Sarat Chandarlapaty, Mathew Thomas, **Halle C. F. Moore, George Thomas Budd**, Wai Hong Wilson Tang, Stanley L. Hazen, Aaron Bernstein, Serena Nik-Zainal, **Jame Abraham**; Cleveland Clinic, Cleveland, OH; Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Memorial Sloan Kettering Cancer Center, New York, NY; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH; Cambridge University, Cambridge, United Kingdom; University of Cambridge, Cambridge, United Kingdom

(11500) **TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results.**
Sarcoma – Bone Tumors
Authors: Joseph Aloysius Ludwig, Noah C. Federman, **Peter Meade Anderson**, Margaret E Macy, Richard F. Riedel, Lara E. Davis, Najat C. Daw, Jade Wulff, AeRang Kim, Ravin Ratan, Edwina S Baskin-Bey, Jeffrey A. Toretsky, James Bradley Breitmeyer, Paul A. Meyers; Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX; Pediatrics, UCLA Medical Center, Los Angeles, CA; Cleveland Clinic Foundation, Cleveland, OH; Pediatric Hematology/Oncology, University of Colorado and Children's Hospital of Colorado, Aurora, CO; Duke Cancer Institute, Duke University Medical Center, Durham, NC; Knight Cancer Institute, Oregon Health & Science University, Portland, OR; Pediatrics, MD Anderson Cancer Center, Houston, TX; Pediatrics, Texas Children’s Hospital, Houston, TX; Children’s National Medical Center, Washington, DC; Oncternal Therapeutics, Inc., San Diego, CA; Departments of Pediatrics and Oncology, Georgetown University, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY

(11503) **P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).**
Sarcoma – Soft Tissue
Authors: Scott Schuetze, Karla V. Ballman, Kristen N. Ganjoo, Elizabeth J. Davis, Jeffrey A. Morgan, Gabriel Tinoco, Melissa Amber Burgess, Brian Andrew Van Tine, Edwin Choy, **Dale Randall Shepard**, ASCO Annual Meeting 2021
Ciara Marie Kelly, Richard F. Riedel, Margaret von Mehren, Brittany L Siontis, Steven Attia, Gary K. Schwartz, Hari Anant Deshpande, Erin Kozlowski, Helen X. Chen, Brian Rubin; University of Michigan, Ann Arbor, MI; Weill Cornell Medicine, New York, NY; Stanford University Medical Center, Stanford, CA; Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Concord, MA; The Ohio State University, Columbus, OH; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO; Massachusetts General Hospital, Boston, MA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Duke University Medical Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Columbia University Irving Medical Center, New York, NY; Yale Cancer Center, New Haven, CT; SARC, Ann Arbor, MI; CTEP National Cancer Institute, Rockville, MD; Cleveland Clinic, Cleveland, OH

(11508) Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.
Sarcoma – Soft Tissue
Authors: Brian Andrew Van Tine, Angela C. Hirbe, Jingqin Luo, Peter John Oppelt, Mia C. Weiss, Vanessa Anne Eulo, Jacqui Toeniskoetter, Sarah Abarchia, Tyler Ruff, John S. Bomalaski, Amanda Johnston, Chih-Ling Kuo, Chiu-Fang Shiu, Matthew Ingham, Nam Bui, Sant P. Chawla, Gary K. Schwartz, Kristen N. Ganjoo; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO; Washington University in St. Louis, St. Louis, MO; University Hospitals Case Medical Center, Cleveland, OH; Washington University School of Medicine, St. Louis, MO; Polaris Pharmaceuticals Inc., San Diego, CA; Polaris Pharmaceuticals, San Diego, CA; Columbia University Irving Medical Center, New York, NY; Stanford University, Stanford, CA; Sarcoma Oncology Research Center, Santa Monica, CA; Stanford University Medical Center, Stanford, CA

Central Nervous System Tumors - Primary CNS Tumors – Glioma
Authors: Eudocia Quant Lee, Lorenzo Trippa, Geoffrey Fell, Rifaquat Rahman, Isabel Arrillaga-Romany, Mehdi Touat, Jan Drappatz, Mary Roberta Welch, Evanthia Galanis, Manmeet Singh Ahluwalia, Howard Colman, Louis B. Nabors, Jaroslaw T. Hepel, David Schiff, David M. Meredith, David A. Reardon, Keith L. Ligon, Brian Michael Alexander, Patrick Y. Wen; Dana-Farber Cancer Institute, Boston, MA; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA; Dana-Farber/Brigham and Women's Cancer Center, Boston, MA; Massachusetts General Hospital, Boston, MA; Hôpital Pitié Salpêtrière, Villejuif, France; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Montefiore Medical Center, New York, NY; Mayo Clinic, Rochester, MN; Rose Ella Burghardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; University of Alabama at Birmingham, Birmingham, AL; New England Medcrl Ctr-Tufts Univ, East Greenwich, RI; University of Virginia, Charlottesville, VA; Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA

(2015) Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
Central Nervous System Tumors - Primary CNS Tumors - Glioma
Authors: Manmeet Singh Ahluwalia, Yasmeen Rauf, Hong Li, Patrick Y. Wen, David M. Peereboom, David A. Reardon; Rose Ella Burghardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig
Cancer Institute and Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

(2017) Superior overall survival (OS) and disease-free survival (DFS) predictions for patients with glioblastoma multiforme (GBM) using Cellworks Singula: myCare-022-03.
Central Nervous System Tumors - Primary CNS Tumors - Glioma
Authors: Patrick Y. Wen, Michael Castro, Drew Watson, Shweta Kapoor, Ashish Agrawal, Aftab Alam, Kunal Ghosh Roy, Swaminathan Rajagopalan, Kabya Basu, Deepak Anil Lala, Nirjhar Mundkur, Jim Christie, Anusha Pampana, Sayani Basu, Diwyanshu Sahu, Yugandhara Narvekar, Divya Singh, Prashant Nair, Manmeet Singh Ahluwalia; Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA; Personalized Cancer Medicine PLLC, Los Angeles, CA; Cell Works Group, Inc., South San Francisco, CA; Cellworks Research India, Bangalore, India; Cellworks Research India, Bangalore, CA, India; Cellworks Group, South San Francisco, CA; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH

(2513) ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.
Developmental Therapeutics—Immunotherapy - New Targets and New Technologies (IO)
Authors: Valentina Boni, Ira Seth Winer, Lucy Gilbert, Ulka N. Vaishampayan, Seth David Rosen, Jameel Muzaffar, Anna Spreafico, David F. McDermott, Quincy S. Chu, Olivier Dumas, Aman Chauhan, Arvind Chaudhry, Piotr Tomczak, Debora S. Bruno, Yangchun Du, Ilda Bidollari, Jessica Martin Rege, Marc S. Ernststoff, James F. Strauss, Vamsidhar Velcheti; START Madrid CIOCC Madrid, Madrid, Spain; Karmanos Cancer Institute, Detroit, MI; McGill University Health Centre, Royal Victoria Hospital, Montréal, QC, Canada; University of Michigan Cancer Center, Detroit, MI; Hem Onc Assoc of the Treasure Coast, Port St Lucie, FL; Moffitt Cancer Center, Tampa, FL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada; Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Centre Hospitalier Universitaire De Quebec, Quebec, QC, Canada; University of Kentucky, Division of Medical Oncology, Lexington, KY; Med Onc Assoc. P. S., Spokane, WA; Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Poznań, Poland; The MetroHealth System, Cleveland, OH; Alkermes, Inc., Waltham, MA; Cleveland Clinic, Cleveland, OH; Mary Crowley Cancer Research Center, Dallas, TX; NYU Langone-Laura and Isaac Perlmutter Cancer Center, New York, NY

(3010) Interim results of PATHFINDER, a clinical use study using a methylation-based multi-cancer early detection test.
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology - New Targets and New Technologies (IO)
Authors: Tomasz M. Beer, Charles H. McDonnell, Lincoln Nadauld, Minetta C. Liu, Eric A. Klein, Robert Lawrence Reid, Catherine Marinac, Karen Chung, Margarita Lopatin, Eric T. Fung, Deborah Schrag; Knight Cancer Institute, Oregon Health & Science University, Portland, OR; Sutter Health, Sacramento, CA; Intermountain Healthcare, St. George, UT; Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; US Oncology Research, Virginia Cancer Specialists, Fairfax, VA; Dana-Farber Cancer Institute, Boston, MA; GRAIL, Inc., Menlo Park, CA

(3015) A first-in-human study of mirzotamab cleuzotoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology - New Targets and New Technologies (IO)
Authors: Anthony W. Tolcher, Benedito A. Carneiro, Afshin Dowlati, Albiruni Ryan Abdul Razak, Young Kwang Chae, Jeannine A. Villella, Sheryl Coppola, Stefan Englert, Andrew C. Phillips, Andrew J. Souers,
Zeena Salman, Sudhir Penugonda, John D. Powderly, Patricia LoRusso; Next Oncology, San Antonio, TX; Brown University, Lifespan Cancer Institute, Providence, RI; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; Princess Margaret Cancer Centre, Toronto, ON, Canada; Northwestern University, Chicago, IL; Northwell Health, New York, NY; AbbVie Inc., North Chicago, IL; AbbVie Deutschland GmbH & Co KG, Data and Statistical Sciences, Ludwigshafen, CA, Germany; Carolina BioOncology Institute, Huntersville, NC; Yale University School of Medicine, New Haven, CT

(3509) Survival and organ preservation according to clinical response after total neoadjuvant therapy in locally advanced rectal cancer patients: A secondary analysis from the organ preservation in rectal adenocarcinoma (OPRA) trial.

Gastrointestinal Cancer—Colorectal and Anal - Colorectal Cancer - Local-Regional
Authors: Hannah Thompson, Jin Ki Kim, Jonathan B. Yuval, Floris Verheij, Sujata Patil, Marc J Gollub, Abraham Jing-Ching Wu, Meghan Lee, Aram F Hezel, Jorge Marcet, Peter Cataldo, Blase N. Polite, Daniel Herzig, David Lisca, Samuel Oommen, Charles Friel, Charles A. Ternent, Andrew L. Coveler, Steven R. Hunt, Julio Garcia-Agullar; Colorectal Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY; NRG Oncology and Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; James P. Wilmot Cancer Institute, University of Rochester, Rochester, NY; Tampa General Hospital, Tampa, FL; University of Vermont, Burlington, VT; University of Chicago Medical Center, Chicago, IL; Oregon Health and Science University, Portland, OR; Cleveland Clinic, Cleveland, OH; John Muir Health, Walnut Creek, CA; University of Virginia, Charlottesville, VA; Colon & Rectal Surgery Inc., Omaha, NE; Seattle Cancer Care Alliance/University of Washington, Seattle, WA; Washington University School of Medicine in St. Louis, St. Louis, MO

(4510) Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).

Genitourinary Cancer—Kidney and Bladder – Kidney Cancer
Author: Michael B. Atkins, Opeyemi Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asim Bilin, Jessica Hawley, Jeffrey A. Sosman, Robert S. Alter, Elizabeth R. Plimack, Moshe Chaim Ornstein, Michael E. Hurwitz, David J. Peace, Sabina Signoretti, Catherine J. Wu, Paul J. Catalano, Hans J. Hammers; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Dana Farber Cancer Institute, Boston, MA; Abramson Cancer Center, University of Pennsylvania (ECOG-ACRIN), Philadelphia, PA; Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; Columbia University Medical Center, New York, NY; Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Fox Chase Cancer Center, Philadelphia, PA; Cleveland Clinic Cancer Center, Cleveland, OH; Yale School of Medicine, New Haven, CT; University of Illinois at Chicago, Chicago, IL; Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX

(6014) TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC).

Head and Neck Cancer – Local-Regional
Authors: Stuart J. Wong, Pedro A. Torres-Saavedra, Nabil F. Saba, George Shenouda, Jeffrey Bumpous, Robert E. Wallace, Christine H. Chung, Adel K. El-Naggar, Clement K Gwede, Barbara Burtness, Paul Tennant, Neal E. Dunlap, Loren K. Mell, Sharon Spencer, William A. Stokes, Min Yao, Darrion L Mitchell, Jonathan Harris, Walter J Curran, Quynh-Thu Le; Medical College of Wisconsin, Milwaukee, WI; NRG Oncology Statistics and Data Management Center, Philadelphia, PA; Winship Cancer Institute of Emory University, Atlanta, GA; McGill University Health Centre, Montréal, QC, Canada; University of Louisville, Louisville, KY; Cedar Sinai

ASCO Annual Meeting 2021
[7]
Cancer Center members indicated in **BOLD**

Medical Center, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; The University of Texas MD Anderson Cancer Center, Houston, TX; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Yale School of Medicine and Yale Cancer Center, New Haven, CT; The James Graham Brown Cancer Center at University of Louisville, Louisville, KY; Moores Cancer Center, La Jolla, CA; University of Alabama at Birmingham, Birmingham, AL; Emory University School of Medicine, Atlanta, GA; Case Comprehensive Cancer Center, University Hospital of Cleveland Medical Center, Cleveland, OH; Ohio Stae University Comprehensive Cancer Center, Columbus, OH; Stanford University, Stanford, CA

**(7010)** Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS).

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant — Myelodysplastic Syndromes (MDS)

Authors: Sangeetha Venugopal, Courtney Denton Dinardo, Koichi Takahashi, Marina Konopleva, Sanam Loghavi, Gautam Borthakur, Amy Elizabeth Dezern, Lucia Masarova, Naval Guastad Daver, Nicholas James Short, Yesid Alvarado, Farhad Ravandi, Guillermo Montalban-Bravo, Koji Sasaki, Ricardo Delumpa, Mikkael A. Sekeres, **Bhumika J Patel**, Gail J. Roboz, Hagop M. Kantarjian, Guillermo Garcia-Manero;

University of Texas MD Anderson Cancer Center, Houston, TX; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas, MD Anderson Cancer Center, Houston, TX; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Weill Cornell University, New York, NY

**(8510)** Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers— Small Cell Lung Cancer

Authors: Taofeek K. Owonikoko, Stéphane Champiat, Melissa Lynne Johnson, Ramaswamy Govindan, Hiroki Izumi, W. Victoria Victoria Lai, Hossein Borghaei, Michael J. Boyer, Rene J. Boosman, Horst-Dieter Hummel, Fiona Blackhall, Afshin Dowlati, Yiran Zhang, Sujoy Mukherjee, Mukul Minocha, Yanchen Zhou, Nooshin Hashemi Sadraei, Luis G. Paz-Ares; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; Drug Development Department (DITEP), Gustave Roussy, Paris-Saclay University, Villejuif, France; Lung Cancer Research, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Divisions of Hematology and Oncology, Washington University Medical School, St. Louis, MO; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Thoracic Oncology Service, Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA; Chris O’Brien Lifehouse, Camperdown, NSW, Australia; The Netherlands Cancer Institute, Amsterdam, Netherlands; Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany; Department of Medical Oncology, The Christie NHS Foundation Trust, Division of Cancer Sciences, Manchester, United Kingdom; Department of Medical Oncology, Hospital Barcelona, Barcelona, Spain; Division of Hematology and Oncology, Department of Medicine, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH; Amgen Inc., Thousand Oaks, CA; Amgen Inc San Francisco, South San Francisco, CA; Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Clinical Research Unit, Universidad Complutense & CiberOnc, Madrid, Spain

**(8514)** Racial differences in incidence, outcomes, and genomic alterations in small cell lung cancer.

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers — Small Cell Lung Cancer

Authors: Leyla Bayat, Pingfu Fu, Shufen Cao, Afshin Dowlati; University Hospital Case Western Medical Center, Cleveland, OH; Department of Population and Quantitative Health Sciences, Case Western Reserve
University, Cleveland, OH; Department of Biostats and Epidemiology, Case Western Reserve University, Cleveland, OH; Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH

(8515) Impact of socioeconomic disparities on diagnosis and overall survival in small cell lung cancer: A National Cancer Database analysis.
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers – Small Cell Lung Cancer Authors: Logan Roof, Wei Wei, Katherine Tullio, Nathan A. Pennell, James Stevenson; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH

(11513) A phase II trial of sitravatinib, a multireceptor tyrosine kinase inhibitor, in patients with advanced well-differentiated/dedifferentiated liposarcoma.
Sarcoma – Soft Tissue Authors: Jay Oza, Sahil Doshi, Shing Mirn Lee, Brian Andrew Van Tine, Edwin Choy, Peter John Oppelt, Shahnaz V. Singh-Kandah, Susana Hernandez, Zoe Singer, Swathi Balaji, Lauren Franks, Matthew Ingham, Gary K. Schwartz; Columbia University Irving Medical Center, New York, NY; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO; Massachusetts General Hospital, Boston, MA; University Hospital Case Medical Center, Cleveland, OH

Poster Sessions

(584) Computational features of tumor-infiltrating lymphocyte architecture of residual disease after chemotherapy on H&E images as prognostic of overall and disease-free survival for triple-negative breast cancer.
Breast Cancer—Local/Regional/Adjuvant – Neoadjuvant Therapy Authors: Germán Corredor, Paula Toro, Cheng Lu, Pingfu Fu, Shaveta Vinayak, Miluska Castillo Garcia, Luis A. Bernabe, Carlos Arturo Castaneda Altamirano, Alberto J. Montero, Aparna Harbhajanka, Hannah L. Gilmore, Anant Madabhushi; Case Western Reserve University, Cleveland, OH; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; NSABP Foundation, Cleveland Clinic, Cleveland, OH; University Hospitals, Cleveland, OH; University Hospitals Case Medical Center, Beachwood, OH; Case Western Reserve University, Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, OH

(1038) Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpressing solid tumors: Results from two phase 1 clinical trials.
Breast Cancer—Metastatic – HER2-Positive Authors: Sara A. Hurvitz, Haeseong Park, Sophia Frentzas, Catherine M. Shannon, Katharine Cuff, Richard Wilhelm Eek, George Thomas Budd, Amelia McCartney, Joyce O'Shaughnessy, Janice M. Lu, Jian Zhang, Dongmei Ji, Weina Shen, Matt Li, Jinchun Yan, Gang Xia, Yanping Ji, Sulan Yao, Gaozhun Xiong, Xichun Hu; David Geffen School of Medicine, University of California, Los Angeles/ Jonsson Comprehensive Cancer Center, Los Angeles, CA; Washington University School of Medicine in St. Louis, St. Louis, MO; Monash Hospital, Victoria, Australia; Mater Cancer Care Centre, South Brisbane, QLD, Australia; Princess Alexandra Hospital, Queensland, Australia; Border Medical Oncology, Wodonga, VIC, Australia; Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH; Monash Medical Centre, Clayton, VIC, Australia; Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Fudan University Shanghai Cancer Center, Shanghai, China; Ambrx, Inc, Princeton Junction, NJ; NovoCodex Biopharmaceuticals, Shanghai, China; Ambrx, Inc., La Jolla, CA; Department of Medical Oncology, Fudan University Cancer Hospital, Shanghai, China

ASCO Annual Meeting 2021
Cancer Center members indicated in BOLD

**(1532)** Choosing unwisely: Low-value care in older adults with a diagnosis of myelodysplastic syndrome.
Care Delivery and Regulatory Policy – Care Delivery/Models of Care
Authors: Sudipto Mukherjee, Weichuan Dong, Kurt C Stange, Jennifer Cullen, Sarah C. Markt, Mikkael A. Sekeres, Siran M. Koroukian; Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Center for Prostate Disease Research, Bethesda, MD; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Case Western Reserve Univ, Cleveland, OH

**(1534)** Are National Cancer Institute Cancer Centers (NCI-CC) providing adolescents and young adults (AYA) with cancer focused clinical services? A national survey.
Care Delivery and Regulatory Policy – Care Delivery/Models of Care
Authors: Katherine Daunov, Michael Daunov, Kara Noskoff, Hilary Gan, Simon Davies, Olivia Larbi, Megan Farrell, Whitney Hadley, Amelia Renee Baffa, Jennifer Giesel, Rachel A. Egler, Alex Yee-Chen Huang, John J. Letterio, Richard T. Lee; Case Western Reserve University, Cleveland, OH; UH Cleveland Medical Center, Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland, OH; Teen Cancer America, Los Angeles, CA; Rainbow Babies & Children's Hospital, Cleveland, OH; University Hospitals, Cleveland, OH; UH Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland, OH; Rainbow Babies and Children's Hospital, Cleveland, OH; Rainbow Babies and Children's Hosp/Case Western Reserve Univ, Cleveland, OH; Department of Pediatrics, Division of Pediatric Hematology/Oncology, University Hospitals Rainbow Babies & Children's Hospital Center, The Angie Fowler Adolescent & Young Adult Cancer Institute, United States, Cleveland, OH

**(1572)** Towards reducing cancer burden within the Medicaid program: Impact of Medicaid expansion on cancer stage at diagnosis.
Care Delivery and Regulatory Policy – Health Policy
Authors: Siran M. Koroukian, Jennifer Tsui, Weichuan Dong, Xiaoyu Yan, Uriel Kim, Johnie Rose, Jeffrey Albert, Kristine M. Zanotti, Cynthia Owusu, Gregory Cooper; Case Western Reserve University, Cleveland, OH; University of Southern California, Los Angeles, CA; University Hospital of Cleveland, Cleveland, OH; Case Western Reserve University School of Medicine, Cleveland, OH

**(1573)** Disparities in government and nonprofit organization funding may hinder clinical trial development for underfunded cancers.
Care Delivery and Regulatory Policy – Health Policy
Author: Suneel Deepak Kamath; Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH

**(1576)** Implementation of insurance marketplaces and changes in diagnosis stage in low-income cancer patients.
Care Delivery and Regulatory Policy – Health Policy
Authors: Uriel Kim, Siran M. Koroukian, Kurt C Stange, James Spilsbury, Johnie Rose; Case Western Reserve University, Cleveland, OH; Case Western Reserve Univ, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

**(2031)** Outcomes of first-generation versus third-generation epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer with brain metastases (NSCLCBM).
Central Nervous System Tumors – Brain Metastases
Authors: Vineeth Tatineni, Patrick Joseph O'Shea, Yasmeen Rauf, Xuefei Jia, Erin Sennett Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet Singh Ahluwalia; Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Department of

ASCO Annual Meeting 2021
Cancer Center members indicated in **BOLD**

Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, University Heights, OH; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH

(2032) Outcomes of immunotherapy (ICI) alone vs tyrosine kinase inhibitors (TKI) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis.

Central Nervous System Tumors – Brain Metastases

Authors: Patrick Joseph O'Shea, Vineeth Tatineni, Yasmeen Rauf, Xuefei Jia, Erin Sennett Murphy, **Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet Singh Ahluwalia**; Cleveland Clinic, Cleveland, OH; Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, University Heights, OH; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH


Central Nervous System Tumors – Brain Metastases

Authors: Vineeth Tatineni, Patrick Joseph O'Shea, Yasmeen Rauf, Xuefei Jia, Erin Sennett Murphy, **Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet Singh Ahluwalia**; Burkhartd Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, University Heights, OH; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH

(2045) Pilot trial treating recurrent GBM patients with precision medicine regimens.

Central Nervous System Tumors – Primary CNS Tumors – Glioma

Authors: Jennifer Leigh Clarke, David Solomon, Nancy Ann Oberheim Bush, Jennifer A. Grabowsky, Cassie Kline, Deanna L. Kroetz, Jennie Webster Taylor, Javier Villanueva-Meyer, Annette Molinaro, David Gibson, Meghan Tedesco, Jane E Rabbitt, Eduardo Rodriguez Almaraz, Jessica Schulte, Robin Arthur Buerki, Shawn L. Hervey-Jumper, Manish K. Aghi, Mitchel S. Berger, Edward Chang, Susan Marina Chang; University of California, San Francisco, San Francisco, CA; University of California San Francisco, San Francisco, CA; UC San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; UC San Francisco, San Francisco, CA; Columbia University Irving Medical Center, New York, NY; University Hospitals Cleveland – Seidman Cancer Center, Cleveland, OH

(2058) Cost-effectiveness of concomitant and adjuvant temozolomide for glioblastoma patients with unmethylated O6-methylguanine-DNA methyltransferase promoter regions in the United States.

Central Nervous System Tumors – Primary CNS Tumors – Glioma

Authors: Manav Dev Midha, Mark Edward Votruba; Department of Economics, Case Western Reserve University, Cleveland, OH; Center for Health Care Research and Policy, Cleveland, OH

(2060) Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.

Central Nervous System Tumors – Primary CNS Tumors – Glioma

Authors: Yasmeen Rauf, Rachel Hufsey, Kathy Robinson, **John H. Suh, Samuel T. Chao**, Erin Sennett Murphy, **Jennifer S. Yu, David M. Peereboom, Manmeet Singh Ahluwalia**, Wei Wei; Cleveland Clinic, Cleveland, OH; Cleveland Clinic, University Heights, OH; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

ASCO Annual Meeting 2021

[11]
(2061) Safety and feasibility of rhenium-186 nanoliposome (186RNL) in recurrent glioma: The ReSPECT phase 1 trial.
Central Nervous System Tumors – Primary CNS Tumors – Glioma
Authors: Andrew J. Brenner, Ande Bao, William Phillips, Gregory Stein, Vibhudutta Awasthi, Toral R. Patel, Jeffrey Weinberg, John Floyd; University of Texas Health San Antonio Cancer Center, San Antonio, TX; Case Western Reserve University, Cleveland, OH; UT Health San Antonio, San Antonio, TX; Plus Therapeutics, Inc., Austin, TX; University of Oklahoma Health Sciences Center, College of Pharmacy, Oklahoma City, OK; UT Southwestern Medical Center, Dallas, TX; MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center at San Antonio, San Antonio, TX

(2545) Using the tumor microenvironment to identify predictors of immunotoxicity to checkpoint inhibitors.
Developmental Therapeutics—Immunotherapy – Inflammatory Signatures
Authors: William Alexander, Kristopher Attwood, Kayla Catalfamo, Grace K. Dy, Saby George, Marc S. Ernstoff, Yara Abdou; University at Buffalo, Buffalo, NY; Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Cleveland Clinic, Cleveland, OH

(2552) Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.
Developmental Therapeutics—Immunotherapy – New targets and New Technologies (IO)
Authors: Omid Hamid, Stephen V. Liu, Ralph V. Boccia, Justin A Call, Trisha Michel Wise-Draper, Angela Tatiana Alistar, John D. Powderly, Bradley Curtis Carthon, Ulka N. Vaishampayan, Anthony J. Olszanski, John M. Wrangle, Anthony Frank Shields, Sarina Anne Anne Piha-Paul, Monali Desai, MD, Yangchun Du, Lei Sun, PhD, Yan Wang, Heather Losey, Craig Hopkinson, Marc S. Ernstoff; The Angeles Clinic and Research Institute, Los Angeles, CA; Georgetown University, Department of Hematology and Oncology, School of Medicine, Washington, DC; Center for Cancer and Blood Disorders, Bethesda, MD; Utah Cancer Spclsts, Salt Lake City, UT; University of Cincinnati Cancer Center, Cincinnati, OH; University of Michigan Cancer Center, Detroit, MI; Fox Chase Cancer Center, Philadelphia, PA; Johns Hopkins Univ School of Medcn, Baltimore, MD; Karmanos Cancer Institute, Wayne State University, Detroit, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; Alkermes, Inc., Waltham, MA; Alkermes Inc, Waltham, MA; Alkermes, Inc, Waltham, MA; Cleveland Clinic, Cleveland, OH

(2643) Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.
Developmental Therapeutics—Immunotherapy – Other IO-related topics
Authors: Hamzah Abu-Sbeih, Tenglong Tang, David M. Faleck, Michael L. Dougan, Anna Olsson-Brown, Douglas Buckner Johnson, Dwight Hall Owen, David Engar Warner, Alexander B Philipp, Nick Powell, Ella Daniels, Jessica Philpott, Alison Margaret Weppler, David James Pinato, Yinghong Wang; University of Missouri, Kansas City, MO; The Second Xiangya Hospital, Central South University, Changsha, China; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital Cancer Center, Boston, MA; The Clatterbridge Cancer Centre, Wirral, United Kingdom; Vanderbilt University Medical Center, Nashville, TN; Division of Medical Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH; Wake Forest Baptist Health, Winston-Salem, NC; Department of Medicine II, University of Munich, Munich, Germany; Imperial College London, London, United Kingdom; Chelsea and Westminster Hospital, Chelsa, United Kingdom; Cleveland Clinic, Cleveland, OH; Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Surgery and Cancer, Imperial College London, London, United Kingdom; The University of Texas MD Anderson Cancer Center, Houston, TX
(3054) Novel imaging biomarkers predict progression-free survival in stage 3 NSCLC treated with chemoradiation and durvalumab.

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology – Molecular Diagnostics and Imaging
Authors: Khalid Jazieh, Mohammadhadi Khorrami, Anas M. Saad, Mohamed M. Gad, Vidya Sankar Viswanathan, Pingfu Fu, Prabhakar Rajiah, Anant Madabhushi, Nathan A. Pennell; Cleveland Clinic Foundation, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH; UT Southwestern Medical Center, Dallas, TX; Case Western Reserve University, Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, OH

(3070) A prespecified interim analysis of the PATHFINDER study: Performance of a multicancer early detection test in support of clinical implementation.

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology – New Targets and New Technologies (non-IO)
Authors: Tomasz M. Beer, Charles H. McDonnell, Lincoln Nadauld, Minetta C. Liu, Eric A. Klein, Robert Lawrence Reid, Karen Chung, Margarita Lopatin, Eric T. Fung, Deborah Schrag; Knight Cancer Institute, Oregon Health & Science University, Portland, OR; Sutter Health, Sacramento, CA; Intermountain Healthcare, St. George, UT; Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; US Oncology Research, Virginia Cancer Specialists, Fairfax, VA; GRAIL, Inc., Menlo Park, CA; Dana-Farber Cancer Institute, Boston, MA

(3071) Performance of a targeted methylation-based multi-cancer early detection test by race/ethnicity.

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology – New Targets and New Technologies (non-IO)
Authors: Wai Hong Wilson Tang, Habte Aragaw Yimer, Mohan K. Tummala, Spencer Shao, Gina G. Chung, Jessica M. Clement, Jingjing Gao, Earl Hubbell, Kathryn Kurtzman, Charles Swanton, Lewis R. Roberts; Cleveland Clinic, Cleveland, OH; The U.S. Oncology Network, Tyler, TX; Mercy Clinic Cancer Center, Springfield, MO; Compass Oncology, Portland, OR; The Christ Hospital Health Network, Cincinnati, OH; Hartford HealthCare Cancer Institute, Hartford, CT; GRAIL, Inc., Menlo Park, CA; The Francis Crick Institute, and University College London Cancer Institute, London, United Kingdom; Mayo Clinic, Rochester, MN


Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology – New Targets and New Technologies (non-IO)
Authors: Habte Aragaw Yimer, Wai Hong Wilson Tang, Mohan K. Tummala, Spencer Shao, Gina G. Chung, Fergus Couch, Jingjing Gao, Oliver Venn, Kathryn Kurtzman, Charles Swanton, Jessica M. Clement; The U.S. Oncology Network, Tyler, TX; Cleveland Clinic, Cleveland, OH; Mercy Clinic Cancer Center, Springfield, MO; Compass Oncology, Portland, OR; The Christ Hospital Health Network, Cincinnati, OH; Mayo Clinic, Rochester, MN; GRAIL, Inc., Menlo Park, CA; The Francis Crick Institute, and University College London Cancer Institute, London, United Kingdom; Hartford HealthCare Cancer Institute, Hartford, CT

(3092) Association of high gene expression levels of ARF6 with the immune microenvironment and prediction of poor outcomes.

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology – New Targets and New Technologies (non-IO)
Authors: Natsuko Kawanishi, Yasmine Baca, Joanne Xiu, Hiroyuki Arai, Francesca Battaglin, Priya Jayachandran, Shivani Soni, Wu Zhang, Philip Agop Philip, Davendra Sohal, Mohd Khushman, Benjamin Adam Weinberg, Michael J. Hall, David J. Park, Anthony Frank Shields, A. Craig Lockhart, Wolfgang Michael Korn, Heinz-Josef Lenz, Emil Lou; Division of Medical Oncology, USC Norris Comprehensive Cancer
Cancer Center members indicated in **BOLD**

Center, Keck School of Medicine, Los Angeles, CA; Caris Life Sciences, Phoenix, AZ; Chiba Cancer Center, Chiba, Japan; USC Keck School of Medicine, Los Angeles, CA; Karmanos Cancer Institute, Detroit, MI; Cleveland Clinic, Cleveland, OH; Mitchell Cancer Institute, Mobile, AR; Georgetown University Hospital, Washington, DC; Fox Chase Cancer Center, Philadelphia, PA; St Jude Heritage Medci Grp, Fullerton, CA; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Washington University School of Medicine in St. Louis, St. Louis, MO; USC Norris Comprehensive Cancer Center, Los Angeles, CA; University of Minnesota School of Medicine, Minneapolis, MN

**(3128)** *The impact of clinical decision making in a molecular tumor board at a tertiary care center.*
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology – Tissue-Based Biomarkers
Authors: Meena Sadaps, Kathryn Demski, Ying Ni, Vicky Konig, Brandie Leach, Emily Mazzei, Pauline Funchain; Cleveland Clinic, Cleveland, OH; Genomic Medicine Institute, Cleveland Clinic Lerner Research Institute, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

**(3129)** *The mutational landscape of the sensitivity of cancer to ionizing radiation.*
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology – Tissue-Based Biomarkers
Authors: Priyanka Gopal, Brian Yard, Aaron Petty, Jessica Castrillon, Jyoti D. Patel, Mohamed E. Abazeed; Northwestern University, Chicago, IL; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Lurie Cancer Center, Northwestern University-Feinberg School of Medicine, Chicago, IL; Northwestern University, Chicago, IL

**(3527)** *Globo H expression in metastatic colorectal cancer (CRC).*
Gastrointestinal Cancer—Colorectal and Anal – Biomarkers/Epidemiology/Outcomes
Authors: Priya Jayachandran, Yasmine Baca, Joanne Xiu, Jian Zhang, Francesca Battaglin, Hiroyuki Arai, Richard M. Goldberg, Benjamin Adam Weinberg, Emil Lou, Michael J. Hall, Moh’d M. Khushman, Davendra Sohal, Shivani Soni, Jingyuan Wang, Wu Zhang, Joshua Millstein, Wolfgang Michael Korn, Heinz-Josef Lenz; Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA; Caris Life Sciences, Phoenix, AZ; West Virginia University Cancer Institute, Morgantown, WV; Georgetown University Hospital, Washington, DC; University of Minnesota School of Medicine, Minneapolis, MN; Fox Chase Cancer Center, Philadelphia, PA; Medical Oncology, The University of South Alabama, Mitchell Cancer Institute, Mobile, AL; Cleveland Clinic, Cleveland, OH; Department of Preventive Medicine, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA

**(4110)** *The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results.*
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – Neuroendocrine/Carcinoid
Authors: Daniel M. Halperin, Melissa Lynne Johnson, Jennifer A. Chan, Lowell L. Hart, Natalie Cook, Vipul M. Patel, Benjamin L. Schlechter, Judith Cave, Afshin Dowlati, Lawrence Scott Blaszkowsky, Tim Meyer, Jennifer Rachel Eads, Daniel Culp, Kristina Kriksciukaitaite, Laura Mei, Mark Bilodeau, Jeffrey Bloss, Matthew H. Kulke; The University of Texas MD Anderson Cancer Center, Houston, TX; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Florida Cancer Specialists and Research Institute, Fort Myers, FL; University of Manchester, Manchester, United Kingdom; Gaston Hem and Onc, Gastonia, NC; Southampton University Hospitals NHS Trust, Brockenhurst, United Kingdom; Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH; Hematology/Oncology, Massachusetts General Hospital, Boston, MA; University College London Cancer Institute, London, United Kingdom; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Tarveda Therapeutics, Inc., Watertown, MA; Boston Medical Center, Boston, MA

ASCO Annual Meeting 2021
(4131) Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505.
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – Pancreatic Cancer
Authors: Davendra Sohal, Mai T. Duong, Robert Boutin, Leon Lenchik, Jiyoon Kim, Namita Gandhi, Muhammad Shaalan Beg, Andrea Wang-Gilliam, James Lloyd Wade, Katherine A Guthrie, Elena Gabriela Chiorean, Syed A. Ahmad, Andrew M. Lowy, Howard S. Hochster, Philip Agop Philip, Victor Tsu-Shih Chang; University of Cincinnati, Cincinnati, OH; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Stanford University, Stanford, CA; Wake Forest University, Winston-Salem, NC; Cleveland Clinic, Cleveland, OH; University of Texas Southwestern Medical Center, Dallas, TX; Washington University School of Medicine in St. Louis, St. Louis, MO; Heartland Cancer Research NCORP, Decatur, IL; Fred Hutchinson Cancer Research Center, and SWOG Statistics and Data Management Center, Seattle, WA; University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA; University of Cincinnati Medical Center, Cincinnati, OH; UCSD Moores Cancer Center, La Jolla, CA; Rutgers Cancer Institute, New Brunswick, NJ; Karmanos Cancer Institute, Detroit, MI; Section of Hematology/Oncology, Veterans Administration New Jersey Health Care System, East Orange, NJ

(4136) Impact of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC).
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – Pancreatic Cancer
Authors: Maahum Mehdi, Mandana Kamgar, Ben George, Aniko Szabo, Kaitlin Annunzio, Bradley W Taylor, Aditya Varnam Shreenivas, Sakti Chakrabarti, James P. Thomas, Susan Tsai, Kathleen K. Christians, Douglas B. Evans, Callisia Clarke, William Adrian Hall, Beth Erickson, Gulrayz Ahmed, Bicky Thapa; Medical College of Wisconsin, Wauwatosa, WI; Medical College of Wisconsin, Milwaukee, WI; Froedtert & The Medical College of Wisconsin, Milwaukee, WI; Mayo Clinic, Rochester, MN; Medical College of Wisconsin and Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI; Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI; NRG Oncology and Medical College of Wisconsin, Milwaukee, WI; Department of Medicine, Cleveland Clinic, Cleveland, OH

(4527) Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.
Genitourinary Cancer—Kidney and Bladder – Bladder Cancer
Authors: Srikala S. Sridhar, Thomas Powles, Yohann Loriot, Miguel A. Climent Durán, Shilpa Gupta, Norihiko Tsuchiya, Aristotelis Biamas, Andrea Aridzono, Anders Ullén, Bo Huang, Nuno Matos Costa, Robert J Laliberte, Alessandra Di Pietro, Cora N. Sternberg, Petros Grivas; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew’s Hospital, London, United Kingdom; Gustave Roussy, INSERMU981, Université Paris-Saclay, Villejuif, France; Instituto Valenciano de Oncología, Valencia, Spain; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH; Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan; Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi, Bologna, Italy; Department of Pelvic Cancer, Genitourinary Oncology Unit, Karolinska University Hospital, Solna, Sweden; Pfizer, Groton, CT; Pfizer, Porto Salvo, Portugal; Pfizer, Cambridge, MA; Pfizer srl, Milan, Italy; Englelander Institute for Precision Medicine, Weill Cornell Medicine, Hematology/Oncology, New York, NY; University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA

Genitourinary Cancer—Kidney and Bladder – Bladder Cancer
Authors: Andrew Lachlan Schmidt, Ziad Bakouny, Chris Labaki, Babar Bashir, Jessica M. Clement, Natasha Catherine Edwin, Daniel Blake Flora, Jennifer Girard, Shuchi Gulati, Clara Hwang, Chinmay Jani,
Gilberto Lopes, Ruben A. Mesa, Gil Redelman-Sidi, Sanjay Mishra, Jeremy Lyle Warner, Toni K. Choueiri; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA; Dana Farber Cancer Institute - (Individuals), Boston, MA; Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA; University of Connecticut Health Center Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT; Cleveland Clinic, Cleveland, OH; Univ Hosp/Univ of Cincinnati, Cincinnati, OH; University of Michigan Rogel Cancer Center, Michigan, MI; University of Cincinnati Medical Center, Cincinnati, OH; Henry Ford Health System, Detroit, MI; Mount Auburn Hospital-Harvard Medical School, Cambridge, MA; University of Miami Miller School of Medicine, Miami, FL; UT Health San Antonio, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; Vanderbilt University Medical Center, Nashville; Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana-Farber Cancer Institute, The Lank Center for Genitourinary Oncology, Boston, MA

(5577) High prevalence of actionable germline variants in unselected endometrial cancer (EC) patients. Gynecologic Cancer – Uterine Cancer
Authors: Monica Levine, Rachel Pearlman, Heather Hampel, Casey Cosgrove, David E. Cohn, Alexis Chassen, Adrian Suarez, Steven E. Waggoner, Caroline Billingsley, Kimberly Erin Resnick, Steve Andrews, Sareena Singh, Eric Jenison, Aine Emma Clements, Robert Neff, Paul J. Goodfellow; The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH; The Ohio State University, Columbus, OH; The Ohio State University Comprehensive Cancer Center, Columbus, OH; The Ohio State University Medical Center, Columbus, OH; University Hospital Health System, Cleveland, OH; University of Cincinnati, Cincinnati, OH; MetroHealth Medical Center, Cleveland, OH; Summa Health, Akron, OH; Aultman Hospital, Canton, OH; Mercy Medical Center, Toledo, OH; OhioHealth, Columbus, OH; TriHealth, Cincinnati, OH; The Ohio State University College of Medicine, Columbus, OH

(5585) Computational features of TIL architecture are differentially prognostic of uterine cancer between African and Caucasian American women. Gynecologic Cancer – Uterine Cancer
Authors: Sepideh Azarianpour Esfahani, Pingfu Fu, Haider Mahdi, Anant Madabhushi; Case Western Reserve University, Cleveland Heights, OH; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Case Western Reserve University, Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, OH

Authors: Ahmad Nader Kassem, Akram Alkrephi, Raul Arroyo Suarez; Metrohealth Medical Center Case Western Reserve University, Cleveland, OH

Authors: Kyle T. Enriquez, Gowri Satyanarayana, Maheen Abidi, Shailesh M Advani, Pamela Egan, Arielle Elkrief, Benjamin French, Christopher Ryan Friese, Clara Hwang, Hina Khan, Gary H. Lyman, Rana R. McKay, Gayathri Nagaraj, Matthew Puc, Elizabeth M Robilotti, Shilpa Gupta, Dimpy P Shah, Trisha Michel Wise-Draper, Peter Paul Yu, Dimitrios Farmakiotis; Vanderbilt University Medical Center, Nashville, TN; University of Colorado, CO; The University of California in Los Angeles, Los Angeles, CA; Rhode Island Hospital, Providence, RI; University of Montreal Research Center (CRCHUM), Montréal, QC, Canada; University of Michigan, Ann Arbor, MI; Henry Ford Health System, Detroit, MI; Albert Einstein College of Medicine, Bronx, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California San Diego, Moores Cancer Center, La Jolla, CA; Loma Linda University Cancer Center, Loma Linda, CA; Virtua Surgical Group, Marlton, NJ; Memorial Sloan-Kettering Cancer Center, New York, NY; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; University of Texas Health Science Center San Antonio, San Antonio, TX; University of Cincinnati Cancer Center, Cincinnati,
Cancer Center members indicated in **BOLD**

OH; Hartford HealthCare Cancer Institute, Hartford, CT; Brown University Warren Alpert Medical School, Providence, RI

**(6566)** Initial report on hospitalized cancer patients with COVID-19 from the National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS).

Health Services Research and Quality Improvement — Outcomes
Authors: Nicholas M. Mark, Ana F. Best, **Alok A. Khorana**, Steven Pergam, Grace E. Mishkin, Melissa Bowman, Andrea M. Denicoff, Lawrence Rubinstein, Lalitha Krishna Shankar, James H. Doroshow, Brian I. Rini, Larissa A. Korde; NCCAPS Study Team; Swedish Medical Center, Seattle, WA; National Cancer Institute, Rockville, MD; Cleveland Clinic-Taussig Cancer Institute, Cleveland, OH; Fred Hutchinson Cancer Research Center, Seattle, WA; The Emes Company, LLC, Rockville, MD; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD; Diagnostic Imaging Branch, National Cancer Institute, Bethesda, MD; National Cancer Institute, Bethesda, MD; Vanderbilt-Ingram Cancer Center, Nashville, TN; Clinical Investigations Branch, National Cancer Institute, Bethesda, MD

**(7023)** Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant – Acute Leukemia
Authors: Scott R. Solomon, Pau Montesinos, Aziz Nazha, Stephen Anthony Strickland, Giovanni Martinelli, Armando Santoro, Roland B. Walter, Rachel J. Cook, Maria Calbacho, Susana Vives, Salman Fazal, Krzysztof Brzózka, Setareh Shamsili, Simone Baldini, Dirk Laurent, Andrea Ugo Enrico Pellacani, Farhad Ravandi; Northside Hospital Cancer Institute, Atlanta, GA; Hospital Universitari i Politècnic La Fe, Valencia, Spain; Cleveland Clinic, Cleveland, OH; Vanderbilt University Medical Center, Nashville, TN; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Humanitas University, Humanitas Clinical and Research Center IRCCS, Milan, Italy; Fred Hutchinson Cancer Research Center, Seattle, WA; Oregon Health & Science University, Portland, OR; Hospital 12 de Octubre, Madrid, Spain; ICO-Hospital Germans Trias i Pujol, Badalona, Spain; Allegheny Health Network, Pittsburgh, PA; Ryvu Therapeutics, Krakow, Poland; Menarini Group, Florence, Italy; MD Anderson Cancer Center, Houston, TX

**(7046)** Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib.

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant - Myeloproliferative Syndromes (MPD)
Authors: Ruben A. Mesa, Stephen T. Oh, **Aaron Thomas Gerds**, Vikas Gupta, John V. Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, Jean-Jacques Kiladjian, Ewa Lech-Maranda, Donal P. McLornan, Jeanne Palmer, Uwe Platzbecker, Jacek Treliński, Kazuya Shimoda, Rafe Donahue, Bryan Strouse, Mark Marion Kowalski, Srdan Verstovsek; UT Health San Antonio, San Antonio, TX; Washington University School of Medicine, St. Louis, MO; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH; Princess Margaret Cancer Centre, Toronto, ON, Canada; Frankston Hospital and Department of Clinical Haematology, Frankston, Australia; Hospital Clinic, IDIBAPS, Barcelona, Spain; Universitair Ziekenhuis Leuven (UZ Leuven), Leuven, Belgium; Medical University in Lublin, Lublin, Poland; Hôpital Saint-Louis and Université de Paris, Paris, France; Institute of Hematology and Transfusion Medicine, Department of Hematology, Centre of Postgraduate Medical Education, Warsaw, Poland; Guy’s and Saint Thomas’ NHS Foundation Trust, London, United Kingdom; Mayo Clinic, Phoenix, AZ; University Hospital Leipzig, Leipzig, Germany; Medical University of Lodz, Lodz, Poland; University of Miyazaki, Miyazaki, Japan; Sierra Oncology, Inc., Vancouver, BC, Canada; Sierra Oncology, Vancouver, BC, Canada; The University of Texas MD Anderson Cancer Center, Houston, TX
(7546) Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analyses from LOTIS 2.

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia – Non-Hodgkin Lymphoma Authors: Paolo Calmi, Weiyun Z. Ai, Juan Pablo Alderuccio, Kirit Ardeshna, Mehdii Hamadani, Brian T. Hess, Brad S. Kahl, John A. Radford, Melhem M. Solh, Anastasios Stathis, Pier Luigi Zinzani, Jay Marshall Feingold, David Ungar, Yajuan Qin, Shui He, Carmelo Carlo-Stella; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, CA; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI; Division of Hematology and Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC; Department of Medicine, Oncology Division, Washington University, St. Louis, MO; NtHR Clinical Research Facility, Christie NHS Foundation Trust and the University of Manchester, Manchester, United Kingdom; Blood & Marrow Transplant Program at Northside Hospital, Atlanta, GA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Institute of Hematology Seràgnoli, University of Bologna, Bologna, Italy; ADC Therapeutics America, Inc., Murray Hill, NJ; Clinical Development, ADC Therapeutics America, Inc, Murray Hill, NJ; Department of Oncology and Hematology, Humanitas Clinical and Research Center – IRCCS, and Humanitas University, Milan, Italy

(7547) Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia – Non-Hodgkin Lymphoma Authors: Michael Wang, Javier Munoz, Andre Goy, Frederick Lundry Locke, Caron A. Jacobson, Brian T. Hill, John Timmerman, Houston Holmes, Samantha Jaglowski, Jan Flinn, Peter A. McSweeney, David Bernard Miklos, Marie José Kersten, Krino Bouabdallah, Max S. Topp, Rhine Shen, Ioana Kloos, Weimnin Peng, Xiang Fang, Patrick M. Reagan; The University of Texas MD Anderson Cancer Center, Houston, TX; Banner MD Anderson Cancer Center, Gilbert, AZ; John Theurer Cancer Center, Hackensack, NJ; Moffitt Cancer Center, Tampa, FL; Dana-Farber Cancer Institute, Boston, MA; Cleveland Clinic Foundation, Cleveland, OH; UCLA David Geffen School of Medicine, Los Angeles, CA; Texas Oncology, Dallas, TX; The Ohio State University Comprehensive Cancer Center, Division of Hematology, Columbus, OH; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Colorado Blood Cancer Institute, Denver, CO; Stanford University School of Medicine, Stanford, CA; Amsterdam UMC, University of Amsterdam, and on behalf of HOVON/LLPC, Amsterdam, Netherlands; CHU Bordeaux, Service d’Hématologie et Thérapie Cellulaire, Bordeaux, France; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany; Kite, A Gilead Company, Santa Monica, CA; University of Rochester Medical Center, Rochester, NY

(7550) Efficacy and safety of the PI3Kδ inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24).

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia – Non-Hodgkin Lymphoma Authors: John M. Pagel, Nishitha Reddy, Deepa Jagadeesh, Anastasios Stathis, Adam Steven Asch, Huda S. Salman, Vaishalee Padgaonkar Kenkre, Jacob Drobnyk Soumerai, Judith Lorin-Sangalang, Igor Gorbatchevsky, Joanne Li, Andrew David Zelenetz; Swedish Cancer Institute, Seattle, WA; Vanderbilt University Medical Center, Nashville, TN; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH; IOSI-Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Oklahoma Health Sciences Center, Oklahoma City, OK; Stony Brook Medical Center, Stony Brook, NY; University of Wisconsin, Madison, WI; Memorial Sloan Kettering Cancer Center, New York, NY; MEI Pharma, Inc., San Diego, CA

(7552) Real-world evidence of axicabtagene ciloleucel (Axi-cell) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia – Non-Hodgkin Lymphoma

ASCO Annual Meeting 2021

[18]
Cancer Center members indicated in BOLD

Authors: Caron A. Jacobson, Frederick Lundry Locke, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David Bernard Miklos, Yi Lin, Miguel-Angel Perales, Matthew Alexander Lunning, Megan Herr, Brian T. Hill, Siddhartha Ganguly, Hua Dong, Sarah Nikiforow, Jing Xie, Hairong Xu, Michele Hooper, Jun Kawashima, Marcelo C. Pasquinini; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Medical College of Wisconsin/Center for International Blood and Marrow Transplant Research, Milwaukee, WI; City of Hope National Medical Center, Duarte, CA; The University of Texas MD Anderson Cancer Center, Department of Lymphoma/Myeloma, Houston, TX; Washington University School of Medicine, St. Louis, MO; Stanford University School of Medicine, Stanford, CA; Division of Hematology, Mayo Clinic, Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; University of Nebraska Medical Center, Omaha, NE; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Cleveland Clinic Foundation, Cleveland, OH; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; Gilead Sciences, Inc., Foster City, CA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Kite Pharma, Santa Monica, CA; Gilead, Santa Monica, CA; Gilead Sci Inc, San Ramon, CA; Medical College of Wisconsin, Milwaukee, WI

(7553) Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies.
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia — Non-Hodgkin Lymphoma Authors: Jacob Drobnyk Soumerai, Deepa Jagadeesh, Huda S. Salman, Izidore S. Lossos, Adam Steven Asch, Nishitha Reddy, Vaishalee Padgaonkar Kenkre, John M. Pagel, Daniel O Persky, Farrukh Tauseef Awan, Catherine S. Magid Diefenbach, Wenying Huang, Judith Llorin-Sangalang, Igor Gorbatchevsky, Andrew David Zelenetz; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH; Stony Brook Medical Center, Stony Brook, NY; Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; University of Oklahoma Health Sciences Center, Oklahoma City, OK; Vanderbilt University Medical Center, Nashville, TN; University of Wisconsin, Madison, WI; Swedish Cancer Institute, Seattle, WA; University of Arizona Cancer Center, Tucson, AZ; Augusta University, Augusta, GA; Perlmutter Cancer Center at NYU Langone Health, New York, NY; MEI Pharma, Inc., San Diego, CA; Memorial Sloan Kettering Cancer Center, New York, NY

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia — Non-Hodgkin Lymphoma Authors: Elise A. Chong, Daniel E. Tsai, Mitchell E. Hughes, Mary Ann C Lim, Behdad D. Besharati, Yvonne El Kassiss, Roy Bloom, Deepa Jagadeesh; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Kidney and Pancreas Transplant Program, University of Pennsylvania, Philadelphia, PA; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH

(8039) Phase Ib trial of vactosertib in combination with pomalidomide in relapsed multiple myeloma: A corticosteroid-free approach by targeting TGF-β signaling pathway.
Hematologic Malignancies—Plasma Cell Dyscrasias – Multiple Myeloma Authors: Ehsan Malek, Sunjin Hwang, Paolo Fabrizio Caimi, Leland L. Metheny, Benjamin Kent Tomlinson, Brenda W. Cooper, Kirsten M. Boughan, Folashade Otegbeye, Molly Gallogly, James Joseph Driscoll, Marcos J.G. De Lima; University Hospitals of Cleveland, Cleveland, OH; MedPacto, Inc., Seoul, South Korea; Adult Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals Cleveland Medical Center, Cleveland, OH; University Hospitals Seidman Comprehensive Cancer Center, Cleveland, OH

Cancer Center members indicated in **BOLD**

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers – Adjuvant Therapy
Authors: Christopher Lemmon, Emily Craig Zabor, **Nathan A. Pennell**; Cleveland Clinic, Cleveland, OH

(8539) **Prognostic value of SUVmax on FDG-PET/CT before and after stereotactic body radiotherapy (SBRT) on recurrence and survival in early-stage non-small cell lung cancer (NSCLC).**
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers – Local-Regional Non-Small Cell Lung Cancer
Authors: Saarang Deshpande, **Tarun Kanti Podder**, Yuxia Zhang, Yiran Zheng, William Grubb, Michael Kharouta, **Philip Aaron Linden**, Tithi Biswas; Case Western Reserve University School of Medicine, Cleveland, OH; University Hospitals, Case Medical Center - Seidman Cancer Center, Cleveland, OH

(8548) **NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC—Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation).**
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers – Local-Regional Non-Small Cell Lung Cancer
Authors: Feng-Ming Spring Kong, Chen Hu, Randall Ten Haken, Ying Xiao, Martha Matuszak, Vera Hirsh, Daniel A. Pryma, Barry A. Siegel, Daphna Y. Gelblum, James Hayman, Clifford Grant Robinson, Billy W. Loo, Gregory M.M. Videtic, Sergio Faria, Catherine Ferguson, Neal E. Dunlap, Vijayananda Kundapur, Rebecca Paulus, Jeffrey D. Bradley, Mitchell Machtyay; Clinical Oncology Department, The University of Hongkong-Shenzhen Hospital, Shenzhen, China; NRG Oncology Statistics and Data Management Center, Philadelphia, PA; University of Michigan, Ann Arbor, MI; University of Pennsylvania, Department of Radiation Oncology, Philadelphia, PA; McGill University Health Centre, Westmount, QC, Canada; Washington University School of Medicine in St. Louis, St. Louis, MO; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford Cancer Institute, Stanford, CA; Cleveland Clinic Foundation, Cleveland, OH; Georgia Cares Minority Underserved NCORP, Augusta, GA; The James Graham Brown Cancer Center at University of Louisville, Louisville, KY; Saskatchewan Cancer Center, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, SK, Canada; Emory University, Atlanta, GA; Penn State Milton S Hershey Medical Center, Hershey, PA

(8549) **The impact of a genomic sequencing classifier (GSC) on clinical decision making in patients with a high-risk lung nodule.**
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers – Local-Regional Non-Small Cell Lung Cancer
Authors: Sonali Sethi, Scott Oh, Alexander Chen, Christina Bellinger, Lori Lofaro, Jennifer Tom, Marla Johnson, Jing Huang, Sangeeta Maruti Bhorade, Giulia Kennedy; Cleveland Clinic, Cleveland, OH; University of California, Los Angeles, Los Angeles, CA; Washington University School of Medicine, St. Louis, MO; Wake Forest School of Medicine, Winston-Salem, NC; Veracyte, Inc., South San Francisco, CA; Veracyte, South San Francisco, CA

(8551) **Early candidate nasal swab classifiers developed using machine learning and whole transcriptome sequencing may improve early lung cancer detection.**
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers – Local-Regional Non-Small Cell Lung Cancer
Authors: **Peter J. Mazzone**, Carla Lamb, Kimberly M. Rieger-Christ, Chakravarthy B. Reddy, Jianghan Qu, Shuyang Wu, Jie Ding, Duncan Whitney, Daniel G. Pankratz, Joshua Babiarz, Lori Lofaro, P. Sean Walsh, Jonathon Wilde, Sangeeta Maruti Bhorade, Jing Huang, Giulia Kennedy, Avrum Spira; Cleveland Clinic, Cleveland, OH; Lahey Hospital and Medical Center, Burlington, MA; University of Utah, Salt Lake City, UT; Veracyte, Inc., San Francisco, CA; Johnson & Johnson, Boston, MA; Veracyte, South San Francisco, CA; Veracyte, Inc., South San Francisco, CA
Cancer Center members indicated in **BOLD**

(8554) **Radical surgery in malignant pleural mesothelioma (MPM): An analysis of SEER database.**
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers – Mesothelioma
Authors: Qian Wang, Yaning Zhang, Meng Ru, Changchuan Jiang, Jessica Tran, Juan P. Wisnivesky, Rajwanth Veluswamy; Department of Medicine, Icahn School of Medicine at Mount Sinai St Luke’s and West, New York, NY; Department of Surgery Cleveland Clinic, Cleveland, OH; Icahn School of Medicine at Mount Sinai, New York, NY; Yale University, New Haven, NY; Divisions of General Internal Medicine and Pulmonary and Critical Care Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

(8572) **Combination of quantitative features from H&E biopsies and CT scans predicts response to chemotherapy and overall survival in small cell lung cancer (SCLC).**
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers – Small Cell Lung Cancer
Authors: Cristian Barrera, Mohammadhadi Khorrrami, **Prantesh Jain, Pingfu Fu**, Kate Butler, Abdullah Osme, Paula Toro, Vidya Sankar Viswanathan, Satyapal Chahar, **Afshin Dowlati, Anant Madabhushi**; Case Western Reserve University, Cleveland, OH; University Hospitals-Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH; University Hospitals, Cleveland, OH; Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH; Case Western Reserve University, Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, OH

(9100) **Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings.**
Lung Cancer—Non-Small Cell Metastatic – Metastatic Non-Small Cell Lung Cancer
Authors: Roger B. Cohen, George Earl Peoples, Toana Kawashima, Bill Arana, Xiaoxing Cui, Lyudmila Bazhenova, Rachel E. Sanborn, Wael A. Harb, **Nathan A. Pennell**, Daniel Morgensztern; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Cancer Insight LLC, San Antonio, TX; Heat Biologics Inc., Morrisville, NC; Heat Biologics Inc, Morrisville, NC; UC San Diego, Moores Cancer Center, San Diego, CA; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR; Horizon Oncology Center, Lafayette, IN; Cleveland Clinic, Cleveland, OH; Washington University School of Medicine, St. Louis, MO

(9117) **Superior overall survival (OS), progression-free survival (PFS), and clinical response (CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks Singula: myCare-022-05.**
Lung Cancer—Non-Small Cell Metastatic – Metastatic Non-Small Cell Lung Cancer
Authors: Vamsidhar Velcheti, Michael Castro, Drew Watson, Shweta Kapoor, Anuj Tyagi, Mohammed Sauban, Aftab Alam, Kunal Ghosh Roy, Swaminathan Rajagopalan, Shruthi Kulkarni, Nirjhar Mundkur, Jim Christie, Rakhi Purushothaman Suseela, Adity Ghosh, Kabya Basu, Diwanshu Sahu, Yashaswini Ullal, Prashant Nair, **Manmeet Singh Ahluwalia**; Cleveland Clinic Foundation, Cleveland, OH; Personalized Cancer Medicine PLLC, Los Angeles, CA; Cell Works Group, Inc., South San Francisco, CA; CellWorks Research India, Bangalore, India; Cellworks Research India, Bangalore, CA, India; Cellworks Group, South San Francisco, CA; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH

(9123) **Analysis of patterns of care and benefit of thoracic radiotherapy for patients with stage IV NSCLC in the immunotherapy-era from a national hospital-based registry.**
Lung Cancer—Non-Small Cell Metastatic – Metastatic Non-Small Cell Lung Cancer
Authors: Michael Kharouta, Andrew Jonathan Gross, Kevin Kelley, **Serah Choi, Tithi Biswas**; University Hospitals, Case Medical Center - Seidman Cancer Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; UCSF, San Francisco, CA

(10583) **Variant reclassification and its impact on clinical care in an Asian cancer center.**

ASCO Annual Meeting 2021
[21]
Cancer Center members indicated in **BOLD**

Prevention, Risk Reduction, and Hereditary Cancer – Genetic Testing  
Authors: Jianbang Chiang, Tze Hao Chia, Sock Hoai Chan, Joanne YY Ngeow; National Cancer Centre Singapore, Singapore, Singapore; Lee Kong Chian School of Medicine, Singapore, Singapore; Cleveland Clinic, Cleveland, OH

**(11020)** Gender disparities in National Institute of Health funding for hematologic malignancies, hematopoietic stem cell transplantation, and cellular therapeutics. 
Professional Development and Education Advances – Education Research  
Authors: Raheel Sufian Siddiqui, Moazzam Shahzad, Mahrusk Majeed, Ali Hussain, Faryal Murtaza, Farhan Khalid, Ayesha Habib, Zobia Aijaz, Syeda Sadia Bukhari, Iqra Anwar, Sehar Altaf, **Faiz Anwer**, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Siddhartha Ganguly, Sunil H. Abhyankar, Joseph McGuirk, Faisal Khosa, Muhammad Umair Mushtaq; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; Department of Internal Medicine, St. Mary’s Medical Center, Huntington, WV; Sentara Albemarle Medical Center, Elizabeth City, NC; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; University of British Columbia, Vancouver, BC, Canada

**(11025)** Improving feedback for hematologists and oncologists in training. 
Professional Development and Education Advances – Education Research  
Authors: Ilana Schlam, Sarah Sewaralthahab, Monica Peravali, Calvin Chou, **Timothy D. Gilligan**, Irina Veytsman, Aarthi G. Shenoy; Medstar Washington Cancer Institute, Washington, DC; Washington Hospital Center, Washington, DC; MedStar Washington Hospital Center, Washington, DC; UCSF School of Medicine, San Francisco, CA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

**(11542)** Phase 1 trial of autologous dendritic cell vaccination with imiquimod immunomodulation in children and adults with refractory sarcoma. 
Sarcoma – Soft Tissue  
Authors: Aditi Dhir, Tulay Koru-Sengul, James Grosso, Gina Z. D’Amato, **Matteo M. Trucco**, Andrew Rosenberg, Eli Gilboa, John M. Goldberg, Jonathan C. Trent, Breeelyn A. Wilky; University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, FL; Department of Public Health Sciences, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL; University of Miami Miller school of Medicine, Miami, FL; Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Cleveland Clinic Lerner College of Medicine, Cleveland, OH; University of Miami-Sylvester Comprehensive Cancer Center, Jackson Memorial Hospital, Miami, FL; University of Miami Miller School of Medicine, Miami, FL; Oncorus, Cambridge, MA; University of Colorado, Aurora, CO

**(TPS2065)** LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma. 
Central Nervous System Tumors – Brain Metastases  
Authors: **Andrew E. Sloan**, Robin Arthur Buerki, Christopher Murphy, Andrea True Kelly, Prakash Ambady, Michael Brown, Nicholas A. Butowski, Robert Cavaliere, William T. Curry, Annick Desjardins, Lisa Franklin, Henry S. Friedman, Matthias Gromeier, LeAnn Jackson, Lori Mixson, Shirley S. Ong, Dina Randazzo, Patrick Y. Wen, Garrett Nichols; University Hospitals Cleveland Medical Center & Seidman Cancer Center, Cleveland, OH; Istari Oncology, Morrisville, NC; Oregon Health and Science University, Portland, OR; Duke University Medical Center, Preston Robert Tisch Brain Tumor Center, Durham, NC; University of California, Department of Neurological Surgery, San Francisco, CA; Baptist MD Anderson Cancer Center, Jacksonville, FL; Mass General Cancer Center, Harvard Medical School, Boston, MA; The Ohio State University Wexner Medical Center, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA

**(TPS2667)** Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies.
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology – New Targets and New Technologies (non-IO)
Authors: Arkadiusz Z. Dudek, Dejan Juric, Afshin Dowlati, Erlene Kuizon Seymour, Jordi Rodon Ahnert, Bingxia Wang, Dennis Huszar, Allison J. Berger, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurchim, Anthony J. Olszanski; University of Minnesota, Department of Medicine, Division of Hematology, Oncology, and Transplantation, Minneapolis, MN, Regions Cancer Care Center, HealthPartners, Saint Paul, MN; Massachusetts General Hospital Cancer Center, Boston, MA; University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH; Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, MI; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA

(TPS3144) A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress).
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology – New Targets and New Technologies (non-IO)
Authors: Amita Patnaik, Emiliano Calvo, Sarina Anne Anne Piha-Paul, Antoine Hollebecque, Vladimir Galva, Juanita Suzanne Lopez, Fadi S. Braiteh, Rachel E. Sanborn, Peigen Zhou, Natalya N. Nazarenko, Afshin Dowlati; START, San Antonio, TX; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, Spain; The University of Texas MD Anderson Cancer Center, Houston, TX; Gustave Roussy Cancer Campus, Department of Drug Development (DITEP), Villejuif, France; Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Drug Development Unit -The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR; Seagen, Inc., Bothell, WA; Seagen Inc., Bothell, WA; Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH

(TPS3149) Phase 1 and phase 2a, first-in-human (FIH) study, of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors.
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology – New Targets and New Technologies (non-IO)
Authors: Melissa Lynne Johnson, Deborah Blythe Doroshow, Tanguy Y. Seiwert, Michael K. Gibson, Vamsidhar Velcheti, Aaron Elliott Lisberg, Shetal Arvind Patel, Matthias Scheffler, Francois Lafleur, Margaret Han Dugan, Sunil Sharma; Sarah Cannon Research Institute, Nashville, TN; Icahn School, New Haven, NY; The University of Chicago Medicine, Chicago, IL; Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN; Cleveland Clinic Foundation, Cleveland, OH; UCLA Jonsson Comprehensive Cancer Center, Santa Monica, CA; University of North Carolina at Chapel Hill, Chapel Hill, NC; Lung Cancer Group Cologne, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Dept. I of Internal Medicine, Cologne, Germany; Dracen Pharmaceuticals, New York, NY; Novartis Pharma, East Hanover, NJ; Translational Genomics Research Institute (TGen), Phoenix, AZ

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – Hepatobiliary Cancer
Authors: Alison M. Schram, Suneel Deepak Kamath, Anthony B. El-Khoueiry, Mitesh J. Borad, Kabir Mody, Amit Mahipal, Lipika Goyal, Vaibhav Sahai, Oleg Schmidt-Kittler, Jinshan Shen, Kai Yu Jen, Alicia Deary, Cori Ann Sherwin, Mahesh Padval, Beni B. Wolf, Vivek Subbiah; Memorial Sloan Kettering Cancer Center, New York, NY; Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH; University of Southern California, Los Angeles, CA; Mayo Clinic, Phoenix, AZ; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN;
Massachusetts General Hospital, Boston, MA; University of Michigan, Ann Arbor, MI; Relay Therapeutics, Cambridge, MA; The University of Texas MD Anderson Cancer Center, Houston, TX

**TPS4176** A phase II open-label study of cpi-613 in combination with modified (m)FOLFIRINOX in patients with locally advanced pancreatic cancer.
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – Pancreatic Cancer
Authors: David Lawrence Bajor, Amr Mohamed, J. Eva Selfridge, Erin E. Anderson, Jeffrey Hardacre, John Brian Ammori, Richard T. Lee, Joel N. Saltzman, Jordan Michael Winter; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Karmanos Cancer Institute, Detroit, MI; University Hospitals Cleveland Medical Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals, Seidman Cancer Center and Department of Surgery, Cleveland, OH; University Hospitals, Cleveland, OH

**TPS4586** A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder.
Genitourinary Cancer—Kidney and Bladder – Bladder Cancer
Authors: Stephen B. Williams, Christopher Cutie, Kirk A Keegan, Bradley Raybold, Milin Acharya, Wei Zhu, Xiang Li, Lang A O'Dondi, Neil Beeharry, Daniel Eidelberg Spratt; University of Texas Medical Branch (UTMB), Galveston, TX; TARIS Biomedical, Lexington, MA; Janssen Research & Development, Raritan, NJ; Janssen Research & Development, Spring House, PA; Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH

**TPS4598** Cyto-KIK: A phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib).
Genitourinary Cancer—Kidney and Bladder – Kidney Cancer
Authors: Karie Runcie, Eric A. Singer, Moshe Chaim Ornstein, Christopher B. Anderson, Matthew Dallos, Jessica Hawley, Emerson A. Lim, Charles G. Drake, Benjamin Izar, Hiram A. Shaish, Mark N. Stein; Columbia University Medical Center, New York, NY; Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ; Cleveland Clinic Cancer Center, Cleveland, OH; Department of Urology, Columbia University Irving Medical Center, New York, NY; Columbia University, New York, NY; Columbia University-Herbert Irving Comprehensive Cancer Center, New York, NY; Herbert Irving Comprehensive Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Department of Radiology, Columbia University Irving Medical Center, New York, NY

**TPS7567** Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia – Chronic Lymphocytic Leukemia (CLL)
Authors: Deborah Marie Stephens, Anna Moseley, Brian T. Hill, John M. Pagel, Mazyar Shadman, Michael Jordan Fisch, Alexey Valeryevich Danilov, David Ng, Anthony R. Mato, Danielle M. Brander, Megan Othus, Steve E. Coutre, Susan Mary O'Brien, Harry Paul Erba; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Cleveland Clinic Foundation, Cleveland, OH; Swedish Cancer Institute, Seattle, WA; Univ of Washington, Seattle, WA; AIM Specialty Health, Chicago, IL; Knight Cancer Institute, Oregon Health & Science University, Portland, OR; University of Utah, Salt Lake City, UT; Memorial Sloan Kettering Cancer Center, New York, NY; Duke University School of Medicine, Durham, NC; SWOG Statistical Center, Seattle, WA; Stanford University School of Medicine, Stanford, CA; University of California, Irvine, Irvine, CA; University of Alabama at Birmingham, Birmingham, AL
Cancer Center members indicated in **BOLD**

**Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).**

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers — Local-Regional Non-Small Cell Lung Cancer

Authors: John M. Varlotto, Zhuoxin Sun, Suresh S. Ramalingam, Heather A. Wakelee, Christine M. Lovly, Kurt R. Oettel, Gregory A. Masters, **Nate Pennell**; Edwards Comprehensive Cancer Center, Huntington, WV; IBCSG Statistical Center, Boston, MA; Winship Cancer Institute of Emory University, Atlanta, GA; Stanford Cancer Institute, Stanford, CA; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN; Gundersen Lutheran Hospital/Clinic, La Crosse, WI; Helen F Graham Cancer Center, Newark, DE; Cleveland Clinic, Cleveland

---

**Potential determinants of radiation-induced lymphocyte decrease and lymphopenia in breast cancer patients by machine learning approaches.**

Breast Cancer—Local/Regional/Adjuvant – Biologic Correlates

Authors: Hao Yu, Fang Chen, Li Yang, Jian-Yue Jin, Feng-Ming Spring Kong; Shenzhen Institutes of Advanced Technology, Shenzhen, China; Hku-Shen Zhen Hospital, Shenzhen, China; Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Case Western Reserve University School of Medicine, Cleveland, OH; Department of Clinical Oncology, University of Hong Kong, Hong Kong, China

---

**Predominance of the luminal B molecular subtype in a group of women with infiltrating breast ductal carcinoma in the Colombian coffee region: Analysis by immunohistochemistry.**

Breast Cancer—Local/Regional/Adjuvant – Biologic Correlates

Authors: Paula Toro, Juliana Pava-De Los Rios, Alex Enrique Pava-Ripoll, Sebastian Chica, Edgar Perez, Manuel Villegas, Juan Paulo Preciado, Camilo Celis, Andrés Felipe Mejía; Case Western Reserve University, Cleveland, OH; Universidad de Manizales, Manizales, Colombia; Hospital Departamental San José de Neira, Manizales, Colombia; Hospital San Juan de Dios, Manizales, Colombia; Clinica Roque Armando Lopez, Manizales, Colombia

---

**Improved survival supports primary endocrine therapy in patients with hormone receptor positive/ HER-2 negative metastatic breast cancer.**

Breast Cancer-Metastatic – Hormone Receptor-Positive

Authors: **Robert Shenk**, Lifen Cao, Jonathan T. Bliggenstorfer, James Michael Martin, Megan E. Miller; University Hospitals Cleveland Medical Center, Cleveland, OH; University Hospitals at Cleveland Medical Center, Cleveland, OH

---

**Surgery provides survival benefit over systemic therapy alone for stage IV triple negative breast cancer: A propensity matched analysis of the National Cancer Database.**

Breast Cancer—Metastatic – Triple-Negative

Authors: Lifen Cao, Jonathan T. Bliggenstorfer, Kavin Sugumar, Christopher W. Towe, Pamela Li, Lisa Rock, **Robert Shenk**, James Michael Martin, Megan E. Miller; University Hospitals at Cleveland Medical Center, Cleveland, OH; University Hospitals Cleveland Medical Center, Cleveland, OH

---

**Telemedicine use and satisfaction amongst radiation oncologists during the COVID-19 pandemic: Evaluation of current trends and future opportunities.**

Care Delivery and Regulatory Policy – Care Delivery/Models of Care

ASCO Annual Meeting 2021

[25]
Authors: Alok Deshane, Nicholas Damico, Michael Kharouta, Anna Wu, GI-Ming WANG, Mitchell Machtay, Aryavarta M. S. Kumar, Serah Choi, Aashish D. Bhatt; Case Western Reserve University School of Medicine, Cleveland, OH; University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; University Hospitals, Case Medical Center - Seidman Cancer Center, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Penn State Milton S Hershey Medical Center, Hershey, PA; Cleveland Clinic, Cleveland, OH; UCSF, San Francisco, CA; Case Western Reserve University, School of Medicine, Cleveland, OH

(e13541) Implementation and impact of a novel multidisciplinary immune-related adverse events tumor board for patients receiving immune checkpoint inhibitor therapy
Care Delivery and Regulatory Policy – Care Delivery/Models of Care
Authors: Abhilasha Pankaj Boruah, Kathryn Demski, Pradnya Dinkar Patil, Cassandra Calabrese, Pauline Funchain; Case Western Reserve University School of Medicine, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(e14004) The brain metastasis journey: Experience from patient, caregiver, and physician surveys on diagnosis and treatment of brain metastases.
Central Nervous System Tumors – Brain Metastases
Authors: Albert Eusik Kim, GI-Ming WANG, Kristin A Waite, Scott Elder, Avery Fine, Manmeet Singh Ahluwalia, Daniel J Brat, Minesh P. Mehta, Robin Page, Erin M. Dunbar, Heather Calderone, Debbie Robins, Ralph DeVitto, Nicole Willmarth, Jill Barnholtz-Sloan, Priscilla Kaliopi Brastianos; Massachusetts General Hospital, Boston, MA; Case Western Reserve University, Cleveland, OH; Penn Schoen Berland (PSB) Research, Washington, DC; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH; Northwestern University, Chicago, IL; Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Core Life Wellness, Libertyville, IL; Piedmont Healthcare, Atlanta, GA; American Brain Tumor Association, Chicago, IL; Case Comprehensive Cancer Center and Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH; Massachusetts General Hospital and Harvard Medical School, Boston, MA

(e14009) Outcomes of ER, PR, HER2, and triple-negative mutated breast cancer with brain metastasis.
Central Nervous System Tumors – Brain Metastases
Authors: Patrick Joseph O'Shea, Vineeth Tatineni, Yasmeen Rauf, Xuefei Jia, Erin Sennett Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet Singh Ahluwalia; Case Western Reserve University, Cleveland, OH; Department of Internal Medicine, Summa Health, Akron, OH; Cleveland Clinic, Cleveland, OH; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, University Heights, OH; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH

(e15557) Variation in the use of genomic testing in patients with metastatic colorectal cancer.
Gastrointestinal Cancer—Colorectal and Anal – Colorectal Cancer - Advanced Disease
Authors: Sarah C. Markt, Benjamin Booker, Wyatt Bensken, Fredrick R Schumacher, Johnie Rose, Gregory S. Cooper, Siran M. Koroukian; Case Western Reserve University, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

(e16109) Predictors of 30-day readmission rate after total gastrectomy in patients with gastric malignancy.
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – Esophageal or Gastric Cancer
(e16193) Predictors of 30-day readmission rate after liver transplant in patients with hepatocellular carcinoma.
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – Hepatobiliary Cancer Authors: Miguel Salazar, Shristi Upadhyay Upadhyay Banskota, Pedro Palacios, Estefania Gauto, Binav Baral, Trilok Shrivastava, Nabin Khanal; Cleveland Clinic, Cleveland, OH; John H. Stroger Jr. Hospital of Cook County, Chicago, IL; John H. Stroger Hospital of Cook County, Chicago, IL; Mayo Clinic Jacksonville Gastroenterology & Hepatology, Jacksonville, FL; John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; John H. Stroger Jr. Hospital of Cook County Internal Medicine, Chicago, IL; Creighton University School of Medicine, Omaha, NE

(e16208) Incidence and patterns of secondary malignancies in patients with neuroendocrine neoplasms: A SEER database analysis.
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – Neuroendocrine/Carcinoid Authors: Meena Sadaps, Neal Mehta, Hong Li, Bassam N. Estfan; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(e16230) Neutrophil extracellular traps (NETs) and thrombosis (Thr) in pancreaticobiliary cancer (PBC).
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – Pancreatic Cancer Authors: Christos Fountzilas, Han Yu, Anm Nazmul Khan, Thejaswini Giridharan, Alok A. Khorana, Renuka V. Iyer, Brahm H. Segal; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Cleveland Clinic-Taussig Cancer Institute, Cleveland, OH

(e16233) Clinical outcomes in pancreatic ductal adenocarcinoma (PDAC) patients with underlying autoimmune disease (AID).
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – Pancreatic Cancer Authors: Gulrayz Ahmed, Kaitlin Annunzio, Aniko Szabo, Daniel Eastwood, Bicky Thapa, Bradley W Taylor, Susan Tsai, Kathleen K. Christians, Callisia Clarke, Douglas B. Evans, William Adrian Hall, Beth Erickson, Mandana Kamgar, Ben George; Medical College of Wisconsin, Milwaukee, WI; Department of Medicine, Cleveland Clinic, Cleveland, OH; Medical College of Wisconsin and Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI; Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI; NRG Oncology and Medical College of Wisconsin, Milwaukee, WI; Froedtert & The Medical College of Wisconsin, Milwaukee, WI

(e16560) Thirty day readmissions and outcomes following radical nephrectomy in renal cell carcinoma: A nationwide analysis.
Genitourinary Cancer—Kidney and Bladder – Kidney Cancer Authors: Trilok Shrivastava, Miguel Salazar, Victor Prado, Estefania Gauto, Binav Baral, Shristi Upadhyay, Maha A.T. Elsebaie; John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; Cleveland Clinic, Cleveland, OH; University of Cincinnati Department of Internal Medicine, Cincinnati, OH; John H. Stroger Jr. Hospital of Cook County, Chicago, IL; John H. Stroger Jr. Hospital of Cook County, Cleveland, IL

(e16581) What happened to the preserved renal parenchyma after partial nephrectomy?
Genitourinary Cancer – Kidney and Bladder – Kidney Cancer

ASCO Annual Meeting 2021
[27]
Cancer Center members indicated in **BOLD**

Authors: **Steven Campbell**, Longbin Xiong, Nguyen Jane, Fangjian Zhou, Zhiling Zhang, Yulu Peng; Cleveland Clinic Glickman Urological and Kidney Institute, Cleveland, OH; Sun Yat-sen University Cancer Center, Guangzhou, China; Center for Urologic Oncology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH

(e17033) **Real-world outcomes among prostate cancer patients with BRCA2 gene variants compared to variants in other homologous DNA repair genes.**

Genitourinary Cancer—Prostate, Testicular, and Penile – Prostate Cancer – Advanced/Castrate-Resistant Authors: Meghan Price, Vishal Vashistha, David Winski, Michael Kelley, Rhonda Bitting, Robert B. Montgomery; Duke University School of Medicine, Durham, NC; Cleveland Clinic Foundation, Cleveland, OH; Durham VA Medical Center, Durham, NC; Durham VA Health Care System, Durham, NC; Durham Veterans Affairs Medical Center, Durham, NC; University of Washington, Seattle, WA

(e17570) **A longitudinal study of the adherence to PORTEC-2 based adjuvant radiotherapy in high-intermediate-risk endometrial adenocarcinoma and associated oncologic outcomes.**

Gynecologic Cancer – Uterine Cancer Authors: Hadi Erfani, Atefeh Rezaei, Anthony Costales; Baylor College of Medicine, Houston, TX; Case Western Reserve University, Cleveland, OH; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX

(e18516) **Racial distribution of clinical trial participants in the United States.**

Health Services Research and Quality Improvement – Disparities/Access to Care Authors: **Monaliben Patel**, Lisa M. Hess, Eric Wen Su, Xiaohong Li, **Debora S. Bruno**; University Hospitals Cleveland Medical Center, Cleveland, OH; Eli Lilly and Company, Indianapolis, IN; The MetroHealth System, Cleveland, OH

(e18558) **Excess body weight association with various cancer: A United States population-based study 2021.**

Health Services Research and Quality Improvement – Disparities/Access to Care Authors: Akram Alkrekshi, Raul Arroyo Suarez, Ahmad Nader Kassem; Metrohealth Medical Center Case Western Reserve University, Cleveland, OH

(e18584) **Estimates of stage-specific preclinical sojourn time across 21 cancer types.**

Health Services Research and Quality Improvement – Outcomes Authors: Michael S. Broder, Sikander Ailawadhi, Himisha Beltran, L. Johnetta Blakely, **George Thomas Budd**, Laurie Carr, Michael Cecchini, Patrick Wayne Cobb, Sarah N. Gibbs, Anuraag Kansal, Ashley Kim, Bradley J. Monk, Lee S. Schwartzberg, Deborah J.L. Wong, Irina Yermilov; Partnership for Health Analytic Research, LLC, Beverly Hills, CA; Mayo Clinic, Jacksonville, FL; Dana Farber Cancer Institute, Boston, MA; Tennessee Oncology, Nashville, TN; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; National Jewish Health, Denver, CO; Yale University, New Haven, CT; SCL Health, Billings, MT; GRAIL, Inc., Menlo Park, CA; Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ; West Cancer Center, Memphis, TN; UCLA Health, Los Angeles, CA

(e18601) **Thirty-day readmission after percutaneous coronary intervention with drug eluting stent in patients with active malignancy.**

Health Services Research and Quality Improvement – Outcomes Authors: Hugo Macchi, Miguel Salazar, Juan Del Cid Fratti, Shrishi Upadhay, Binav Baral, Trilok Shrivastava, Estefania Gauto, Juan Adolfo Cattoni; Advocate Masonic Medical Center, Chicago, IL; Cleveland Clinic, Cleveland, OH; OSF Saint Francis Medical Center Cardiovascular Disease Department, Peoria, IL; John H.
Cancer Center members indicated in **BOLD**

Stroger Jr. Hospital of Cook County, Cleveland, IL; John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; John H. Stroger Jr. Hospital of Cook County, Chicago, IL; Providence Hosp and Med Ctr, Southfield, MI

**(e18602)** In-hospital outcomes of transcatheter aortic valve replacement (TAVR) in patients with localized and metastatic malignancy.
Health Services Research and Quality Improvement – Outcomes
Authors: Hugo Macchi, Miguel Salazar, Juan Del Cid Fratti, Estefania Gauto, Binav Baral, Trilok Shrivastava, Shristi Upadhyay Upadhyay Banskota, Maryam Zia, Nabin Khanal; Advocate Masonic Medical Center, Chicago, IL; Cleveland Clinic, Cleveland, OH; OSF Saint Francis Medical Center Cardiovascular Disease Department, Peoria, IL; John H. Stroger Jr. Hospital of Cook County, Chicago, IL; John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; John H. Stroger Hospital of Cook County, Chicago, IL; Univ of Illinois At Chicago, Chicago, IL; Creighton University School of Medicine, Omaha, NE

Health Services Research and Quality Improvement – Outcomes
Authors: Sibgha Gull Chaudhary, Muhammad Usman Zafar, Maha Awais Hassan, Moazzam Shahzad, Ali Hussain, Fatima Ali, Yumna Riaz, Fatima Khalid, Sharad Khurana, Ramesh Balusu, Nausheen Ahmed, Anurag K Singh, **Faiz Anwer**, Sunil H. Abhyankar, Joseph McGuirk, Muhammad Umair Mushtaq; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; Lehigh Valley Health Network, Allentown, PA; Department of Internal Medicine, St. Mary's Medical Center, Huntington, WV; Sentara Albemarle Medical Center, Elizabeth City, NC; Lincoln Medical Center, New York, NY; University of Arizona College of Medicine, Tucson, AZ; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

**(e18620)** 30-day readmission after TAVR (Transcatheter Aortic Valve Replacement (TAVR) in patients with malignancy.
Health Services Research and Quality Improvement – Outcomes
Authors: Shristi Upadhyay Upadhyay, Miguel Salazar, Estefania Gauto, Hugo Macchi, Prajwal Shrestha, Nabin Khanal; John H. Stroger Hospital of Cook County, Chicago, IL; Cleveland Clinic, Cleveland, OH; John H. Stroger Jr. Hospital of Cook County, Chicago, IL; Advocate Masonic Medical Center, Chicago, IL; John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; Creighton University School of Medicine, Omaha, NE

Health Services Research and Quality Improvement – Real-World Data
Authors: Binav Baral, Miguel Salazar, Victor Prado, Estefania Gauto, Shristi Upadhyay, Trilok Shrivastava, Navika Chhabra, Fred R. Rosen; John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; Cleveland Clinic, Cleveland, OH; University of Cincinnati Department of Internal Medicine, Cincinnati, OH; John H. Stroger Jr. Hospital of Cook County, Chicago, IL; John H. Stroger Jr. Hospital of Cook County, Cleveland, IL

**(e18863)** Risk factors for 30-day readmissions in patients with tumor lysis syndrome and solid malignancies: Analysis from the National Readmission Database.
Health Services Research and Quality Improvement – Value/Cost of Care
Authors: Estefania Gauto, Miguel Salazar, Shristi Upadhyay, Binav Baral, Maryam Zia, Trilok Shrivastava, Juan Adolfo Cattoni; John H. Stroger Jr. Hospital of Cook County, Chicago, IL; Cleveland Clinic, Cleveland, OH; John H. Stroger Jr. Hospital of Cook County, Cleveland, IL; John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; Providence Hosp and Med Ctr, Southfield, MI

ASCO Annual Meeting 2021
[29]
(e19014) Outcomes with preemptive donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes: A systematic review and meta-analysis.

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant—Acute Leukemia

Authors: Syed Ather Hussain, Atif N Khan, Venkata S Thammineni, Muhammad Nauman Riaz, Moazzam Shahzad, Priyanjali Pulipati, Fatima Khalid, Zahoor Ahmed, Iqra Anwar, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Sharad Khurana, **Faiz Anwer**, Muhammad Umair Mushtaaq; Rochester General Hospital, Rochester, NY; Larkin Community Hospital, South Miami, FL; Rapides Regional Medical Center, Alexandria, LA; Department of Internal Medicine, St. Mary's Medical Center, Huntington, WV; St. Joseph Mercy Oakland, Pontiac, MI; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; King Edward Medical University, Lahore, Pakistan; University of Kansas Medical Center, Westwood, KS; University of Arizona College of Medicine, Tucson, AZ; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(e19016) Perianal disease remains an understudied and difficult complication in leukemia patients.

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant—Acute Leukemia

Authors: Shreya Gupta, Nirav Patil, Emily Steinhagen-Golbig, **Benjamin Kent Tomlinson**, Sharon Stein, Ronald Charles; University Hospitals, Case Medical Center, Cleveland, OH; University Hospitals, Cleveland Medical Center, Cleveland, OH

(e19021) Outcomes with CD34 stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation for hematologic malignancies: A systemic review and meta-analysis.

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant—Allogenic Stem Cell Transplantation

Authors: Moazzam Shahzad, Iqra Anwar, Raheel Sufian Siddiqui, Tehniat Faraz Ahmed, Mahrulk Majeed, Maha Awaiz Hassan, Zahoor Ahmed, Karun Neupane, Tayyaba Ali, Muhammad Salman Faisal, Masooma Naseem, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Anurag K Singh, Sunil H. Abhyankar, Joseph McGuirk, **Faiz Anwer**, Muhammad Umair Mushtaaq; Department of Internal Medicine, St. Mary’s Medical Center, Huntington, WV; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; Dow University of Health Sciences, Karachi, Pakistan; King Edward Medical University, Lahore, Pakistan; Manipal College of Medical Sciences, Pokhara, Nepal; Department of Hematology, BMT, Ohio State University, Columbus, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(e19035) Outcomes with venetoclax in myelodysplastic syndromes: A systematic review.

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant—Myelodysplastic Syndromes (MDS)

Authors: Razwana Khanam, Moazzam Shahzad, Pranali Santhoshini Pachika, Zahoor Ahmed, Fatima Ali, Adeel Masood, Zunairah Shah, Asmi Chattaraj, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Sharad Khurana, **Faiz Anwer**, Sunil H. Abhyankar, Joseph P McGuirk, Muhammad Umair Mushtaaq; University of Pittsburgh Medical Center, McKeesport, PA; Department of Internal Medicine, St. Mary's Medical Center, Huntington, WV; King Edward Medical University, Lahore, Pakistan; Lincoln Medical Center, New York, NY; TidalHealth Peninsula Regional, Salisbury, MD; Louis A Weiss Memorial Hospital, Chicago, IL; University Pittsburgh Medical Center, McKeesport, PA; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; University of Arizona College of Medicine, Tucson, AZ; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS; Division of Hematologic Malignancies and Cellular Therapeutics University of Kansas Medical Center, Westwood, KS
(e19045) A systematic review of post-transplant lymphoproliferative disorder after liver transplant.
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant - Other
Authors: Mobeen Zaka Haider, Zarlakhta Zamani, Hasan Mehmood Mirza, Hafsa Shahid, Muhammad Taqi, Yousra Khalid, Mohsin Sheraz Mughal, Fnu Kiran, Deepak Kumar, Ahsan Wahab, Muhammad Salman Faisal, Muhammad Umair Mushtaq, Faiz Anwer; King Edward Medical University, Lahore, Pakistan; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA; Mayo Hospital, Lahore, Pakistan; Rutger/RWJ/Monmouth Medical Center, Long Branch, NJ; Department of Pathology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan; Jinnah Postgraduate Medical Center, Karachi, Pakistan; Baptist Medical Center South/University of Alabama Birmingham, Montgomery, AL; Department of Hematology, BMT, Ohio State University, Columbus, OH; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(e19046) A systematic review of post-transplant lymphoproliferative disorder after lung transplant.
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant - Other
Authors: Mobeen Zaka Haider, Zarlakhta Zamani, Fnu Kiran, Hasan Mehmood Mirza, Muhammad Taqi, Hafsa Shahid, Deepak Kumar, Karun Neupane, Yousra Khalid, Mohsin Sheraz Mughal, Muhammad Salman Faisal, Muhammad Umair Mushtaq, Faiz Anwer; King Edward Medical University, Lahore, Pakistan; Department of Pathology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA; Mayo Hospital, Lahore, Pakistan; Jinnah Postgraduate Medical Center, Karachi, Pakistan; Manipal College of Medical Sciences, Pokhara, Nepal; Rutger/RWJ/Monmouth Medical Center, Long Branch, NJ; Department of Hematology, BMT, Ohio State University, Columbus, OH; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(e19508) The impact of atrial fibrillation on hospitalization outcomes for patients with chronic lymphocytic leukemia: A large database analysis.
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia - Chronic Lymphocytic Leukemia (CLL)
Authors: Mohammad Ammad Ud Din, Samarthkumar Thakkar, Harsh P. Patel, Syed Ather Hussain, Aneeqa Zafar, Hania Liaqat, Zunairah Shah, Sarju Ganatra, Muhammad Umair Mushtaq, Faiz Anwer; Rochester General Hospital, Rochester, NY; Louis A Weiss Memorial Hospital, Chicago, IL; El Camino Hospital, Mountain View, CA; Lahey Hospital and Medical Center, Burlington, MA; University of Wisconsin Carbone Cancer Center, Madison, WI; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(e19577) A systematic review of post-transplant lymphoproliferative disorder after renal transplantation.
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia – Other
Authors: Zarlakhta Zamani, Mobeen Zaka Haider, Muhammad Taqi, Hasan Mehmood Mirza, Deepak Kumar, Hafsa Shahid, Fnu Kiran, Yousra Khalid, Mohsin Sheraz Mughal, Usman Ali Akbar, Muhammad Salman Faisal, Muhammad Umair Mushtaq, Faiz Anwer; King Edward Medical University, Lahore, Pakistan; Mayo Hospital, Lahore, Pakistan; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA; Jinnah Postgraduate Medical Center, Karachi, Pakistan; Department of Pathology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan; Rutger/RWJ/Monmouth Medical Center, Long Branch, NJ; University of Louisville, Louisville, KY; Department of Hematology, BMT, Ohio State University, Columbus, OH; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
(e20032) Role of adjunct plasma exchange or high cut-off hemodialysis in the management of myeloma cast nephropathy: A systematic review.
Hematologic Malignancies-Plasma Cell Dyscrasia – Multiple Myeloma
Authors: Nazma Hanif, Muhammad Khawar Sana, Basel Abdelazeem, Abdul Rafae, Muhammad Umair Mushtaq, Faiz Anwer; Foundation University Medical College, Islamabad, Pakistan; King Edward Medical University, Lahore, Pakistan; McLaren Flint Michigan State University, Flint, MI; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(e20034) Recent updates on bispecific T-cell engager (BiTE) antibodies in relapsed and refractory multiple myeloma.
Hematologic Malignancies—Plasma Cell Dyscrasia– Multiple Myeloma
Authors: Abdul Rafae, Ahsan Wahab, Hamid Ehsan, Joshua Christy, Tabinda Saleem, Emad Kandah, Rabia Ali, Mustafa Nadeem Malik, Sundas Ali, Sara Saeed, Faiz Anwer; Department of Internal Medicine, McLaren-Flint/MSU, Flint, MI; Baptist Medical Center South/University of Alabama Birmingham, Montgomery, AL; Georgetown University, Washington DC, DC; UPMC Pinnacle, Harrisburg, PA; Internal Medicine, McLaren Flint-Michigan State University, Flint, MI; Rawalpindi Medical University, Rawalpindi, Pakistan; University of Arizona, Department of Internal Medicine, Tucson, AZ; Wah Medical College, Wah, Pakistan; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(e20037) Choosing optimal therapy for relapsed refractory multiple myeloma: A systematic review and network meta-analysis.
Hematologic Malignancies-Plasma Cell Dyscrasia – Multiple Myeloma
Authors: Mahum Nadeem, Samiksha Gupta, Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz, Rajeshkhar Chakraborty, Mohammed A. Aljama, Muhammad Husnain; University of Oklahoma, Oklahoma, OK; Dow University of Health Sciences, Karachi, Pakistan; Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; University of Miami/Sylvester Cancer Center, Miami, FL

(e20039) Recent updates on three drug combination regimen for relapsed refractory multiple myeloma.
Hematologic Malignancies—Plasma Cell Dyscrasia – Multiple Myeloma
Authors: Tabinda Saleem, Abdul Rafae, Joshua Jonathan Christy, Kiran Kuriakose, Mustafa Nadeem Malik, Emad Kandah, Hafiz Qurashi, Rabia Ali, Faiz Anwer; UPMC Pinnacle, Harrisburg, PA; McLaren Flint Michigan State University, Flint, MI; Internal Medicine, McLaren Flint- Michigan State University, Flint, MI; UPMC McKeesport, Pittsburgh, PA; University of Arizona, Department of Internal Medicine, Tucson, AZ; UPMC Pinnacle, Harrisburgh, PA; Rawalpindi Medical University, Rawalpindi, Pakistan; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(e20042) Management of light chain deposition disease: A systematic review.
Hematologic Malignancies—Plasma Cell Dyscrasia - Plasma Cell Disorders
Authors: Adeel Masood, Moazzam Shahzad, Ahsan Wahab, Pranali Santoshoshini Pachika, Tehnlati Faraz Ahmed, Razwana Khanam, Hamid Ehsan, Karun Neupane, Saher Nasir Amin, Muhammad Umair Mushtaq, Faiz Anwer; TidalHealth Peninsula Regional, Salisbury, MD; Department of Internal Medicine, St. Mary's Medical Center, Huntington, WV; Baptist Medical Center South/University of Alabama Birmingham, Montgomery, AL; University of Pittsburgh Medical Center, McKeesport, McKeesport, PA; Dow University of Health Sciences, Karachi, Pakistan; Georgetown University, Washington DC, DC; Manipal College of Medical Sciences, Pokhara, Nepal; Richmond University Medical Center, Staten Island, NY; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

ASCO Annual Meeting 2021
[32]

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers – Biologic Correlates
Authors: Hao Yu, Li Yang, Ka-On Lam, Jian-Yue Jin, Chen Hu, Feng-Ming Spring Kong; Shenzhen Institutes of Advanced Technology, Shenzhen, China; Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Case Western Reserve University School of Medicine, Cleveland, OH; NRG Oncology Statistics and Data Management Center, Philadelphia, PA; Department of Clinical Oncology, University of Hong Kong, Hong Kong, China

Multivalent state transitions regulate the intratumoral composition of small cell lung carcinoma.

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers – Small Cell Lung Cancer
Authors: Priyanka Gopal, Aaron Petty, Rohan Bareja, Titas Bera, Kevin Rogacki, Jyoti D. Patel, Craig Peacock, Mohamed E. Abazeed; Northwestern University, Chicago, IL; Cleveland Clinic, Cleveland, OH; Case Western Reserve University, Cleveland, OH; University of Toledo College of Medicine and Life Sciences, Toledo, OH; Vanderbilt University Medical Center, Nashville, TN; Lurie Cancer Center, Northwestern University-Feinberg School of Medicine, Chicago, IL; Northwestern University, Chicago, IL

Outcomes of KRAS mutated, EGFR mutated, ALK mutated and wildtype patients in non-small cell lung cancer brain metastases.

Lung Cancer—Non-Small Cell Metastatic – Biologic Correlates
Authors: Yasmeen Rauf, Vineeth Tatineni, Patrick Joseph Oshea, Xuefei Jia, David M. Peereboom, Mannmeet Singh Ahluwalia; Cleveland Clinic, Cleveland, OH; Department of Internal Medicine, Summa Health, Akron, OH; CWRU, Cleveland, OH; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH

Role of capmatinib in MET exon 14-mutated advanced non-small cell lung cancer (NSCLC): A systematic review.

Lung Cancer—Non-Small Cell Metastatic – Metastatic Non-Small Cell Lung Cancer
Authors: Israr Khan, Faiza Ahmed, Nazma Hanif, Mobeen Zaka Haider, Farhan Khalid, Sakshi Mishra, Radhika Garimella, Kim Andrews, Ramya Pakala, Sirisha Gara, Prathima Guntpalli, Faris Pacha, Karthik Mohan, Andre Thompson, Mohamad Mouchli, Godsgift Enebong Nya; Larkin Community Hospital, South Miami, FL; Foundation University Medical College, Islamabad, Pakistan; King Edward Medical University, Lahore, Pakistan; Prince Mohammad Bin Fahad University, Al Khobar, Saudi Arabia; Mississauga Health Centre, Missisauga, ON, Canada; Cleveland Clinic, Cleveland, OH; John Hopkins Hospital, Baltimore, MD

Real-world outcomes of patients with advanced non-small cell lung cancer and driver mutations treated with frontline immunotherapy and/or chemotherapy.

Lung Cancer—Non-Small Cell Metastatic – Metastatic Non-Small Cell Lung Cancer
Authors: Bharathi Muthusamy, Nathan A. Pennell, Andrew J. Belli, Eric Hansen, Victoria Devincenzo, Shubha Shankaranarayana, Ming He, Ching-Kun Wang; Cleveland Clinic, Cleveland, OH; COTA, Inc., Boston, MA

Cellworks Omics Biology Model (CBM) to identify amplifications of chromosome 11p and 1p predict paclitaxel and carboplatin resistance.

Lung Cancer—Non-Small Cell Metastatic – Metastatic Non-Small Cell Lung Cancer
Authors: Michael Castro, Ansu Kumar, Himanshu Grover, Vivek Patil, Prashant Nair, Srushti P Chafekar, Rakhi Purushothaman Suseela, Samiksha Prasad, Chandan Kumar, Vishwas Joseph, Nirjhar Mundkur, Pallavi Kumari, Anusha Pampana, Vijayashree P S, Ashish Choudhary, Veena Balakrishnan, Zakir Husain, Ashokraja Balla, Naga Ganesh, Vamsidhar Velcheti; Personalized Cancer Medicine PLLC, Los Angeles, CA; Cellworks Research India, Bangalore, India; Cellworks Research India, Bangalore, CA, India; Cell Works Group, Inc., South San Francisco, CA; Cleveland Clinic Foundation, Cleveland, OH

(e21211) Cellworks Omics Biology Modeling (CBM) to predict therapy response and identifies novel biomarkers for carboplatin/cisplatin along with pemetrexed in NSCLC patients.
Lung Cancer-Non-Small Cell Metastatic – Metastatic Non-Small Cell Lung Cancer
Authors: Ansu Kumar, Vamsidhar Velcheti, Michael Castro, Himanshu Grover, Subrat Mohapatra, Samiksha Prasad, Deepak Anil Lala, Chandan Kumar, Pallavi Kumari, Reshma P Gopi, Mamatha Patil, Shruthi Kulkarni, Nirjhar Mundkur, Annapoorna Prakash, Rema Mandal, Nagendra Prasad, Sayantani Roy Choudhury, Anish Raju Arora, Liptimayee Behura; Cellworks Research India, Bangalore, India; Cleveland Clinic Foundation, Cleveland, OH; Personalized Cancer Medicine PLLC, Los Angeles, CA; Cellworks Research India, Bangalore, CA, India; Cell Works Group, Inc., South San Francisco, CA

(e21500) Impact of BRAF mutations on outcomes in metastatic melanoma with central nervous system metastases treated with immune checkpoint inhibitors.
Melanoma/Skin Cancers – Advanced Disease
Authors: Hong De Sa, Demetrius Dedousis, Sree Harsha Tirumani, Fatemeh Ardehshir-Larijani, Ariel Ann Nelson, Petra Martin, Prateek Mendiratta, Andrew E. Sloan, Serah Choi, David B. Mansur, Jennifer Eva Selfridge, Nikhil H. Ramaiya, Christopher J. Hoimes; University Hospitals Cleveland Medical Center, Cleveland, OH; University Hospitals, Case Medical Center - Cleveland VA Hospital, Cleveland, OH; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH; Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, IN; Medical College of Wisconsin, Milwaukee, WI; University College Dublin, Dublin, Ireland; University Hospitals Seidman Cancer Center/Case Comprehensive Cancer Center, Cleveland, OH; University Hospital Case Medical Center, Cleveland, OH; UCSF, San Francisco, CA; Univ Hosps Seidman Cancer Ctr, Cleveland, OH; Dana-Farber Cancer Institute, Boston, MA; Duke Cancer Center, Durham, NC

(e21520) Outcomes of stage IV melanoma in the era of immunotherapy (IO): A National Cancer Database (NCDB) analysis.
Melanoma/Skin Cancers – Advanced Disease
Authors: Tamara A. Sussman, Wei Wei, Pauline Funchain, Brian Gastman; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic, Cleveland, OH

(e21525) Metastatic site-specific utilization and outcome of immunotherapy in stage IV melanoma: A national perspective.
Melanoma/Skin Cancers – Advanced Disease
Authors: Lifen Cao, Jonathan T. Bliggenstorfer, Christopher W. Towe, Ankit Mangla, Megan E. Miller, Luke Rothermel; University Hospitals at Cleveland Medical Center, Cleveland, OH; University Hospitals Cleveland Medical Center, Cleveland, OH; University Hospitals-Seidman Cancer Center, Cleveland, OH; University Hospitals, Seidman Cancer Center and Department of Surgery, Cleveland, OH

(e21549) Talimogene laherparepvec with systemic immunotherapy in melanoma: A real-world experience.
Melanoma/Skin cancers – Advanced Disease
Authors: Tapas Ranjan Behera, Yanwen Chen, Jung Min Song, Steve Shih-lin Huang, Pauline Funchain, Brian Gastman; Cleveland Clinic, Cleveland, OH; Taussig Cancer Center at Cleveland Clinic - Mansfield, Mansfield, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(e21550) Impact of immunotherapy on survival differences in patients with melanoma and chronic lymphocytic leukemia.
Melanoma/Skin cancers – Advanced Disease
Authors: Raghav Tripathi, Jeremy S. Bordeaux, Luke Rothermel, Ankit Mangla; Case Western Reserve University School of Medicine, Cleveland, OH; Department of Dermatology, University Hospitals Case Medical Center, Cleveland, OH; University Hospitals Seidman Cancer Center and Department of Surgery, Cleveland, OH; Case Western Reserve University, School of Medicine, Cleveland, OH

(e21560) Circulating tumor DNA mutation as a prognostic marker in melanoma with brain metastasis.
Melanoma/Skin Cancer – Biologic Correlates
Authors: Tapas Ranjan Behera, Jung Min Song, Donald Matthew Eicher, Brian Gastman, Daniel H. Farkas, Pauline Funchain; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Fndtn, Broadview Heights, OH

(e21589) Improved risk stratification in an adjuvant radiation therapy (ART) eligible cutaneous squamous cell carcinoma (cSCC) patient population by integration of the 40-gene expression profile prognostic test (40-GEP)
Melanoma/Skin Cancers – Other
Authors: Shlomo A. Koyfman, Ashley Wysong, Sarah Arron, Alvy Khan B. Somani, Jennifer Siegel, Alison Fitzgerald, Sarah J. Kurley, Matthew S. Goldberg, Chrysalyne Schmults, Jason Newman; Cleveland Clinic, Cleveland, OH; University of Nebraska Medical Center, Omaha, NE; University of California, San Francisco, San Francisco, CA; Indiana University School of Medicine, Indianapolis, IN; Castle Biosciences, Inc., Friendswood, TX; Brigham & Women's Hospital, Boston, MA; University of Pennsylvania, Philadelphia, PA

(e21595) Cytotoxic t lymphocyte (CTL) to macrophage ratio to predict survival in stage II-III melanoma: Validation in a second cohort.
Melanoma/Skin Cancers – Other
Authors: A. Reza Djavid, Benjamin T. Fullerton, Samuel W. Wang, Meghan S. Drastal, Luke W. Barker, Robyn D. Gartrell, Bethany R. Rohr, Tammie C. Ferringer, Yvonne M. Saenger; Columbia University Vagelos College of Physicians and Surgeons, New York, NY; Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY; Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Columbia University Irving Medical Center, New York, NY; Department of Dermatology, University Hospitals Cleveland Medical Center/Case Western Reserve University School of Medicine, Cleveland, OH; Departments of Dermatology and Laboratory Medicine, Geisinger Health System, Danville, PA

(e22002) Comprehensive genomic and transcriptomic profiling of pediatric malignancies using the Tempus xT Next-Generation Sequencing Assay to identify clinically meaningful alterations.
Pediatric Oncology – Pediatric Solid Tumors
Authors: Stephanie Toll, Aneta Kwiatkowska-Piwowarczyk, Jeff Schaeffer, Anna Ewa Schwarzbach, Stefanie Marie Thomas, Kristiyana Kaneva; Children's Hospital of Michigan, Detroit, MI; Tempus, Stoneham, MA; Tempus Labs, Inc., Chicago, IL; Asuragen Inc, Austin, TX; Cleveland Clinic Children’s, Cleveland, OH; Tempus Lab, Chicago, IL

ASCO Annual Meeting 2021
Cancer Center members indicated in **BOLD**